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But whatever were gains to me I now consider loss for the sake of Christ. What is more, I consider 
everything a loss because of the surpassing worth of knowing Christ Jesus my Lord, for whose sake I 
have lost all things. I consider them garbage that I may gain Christ and be found in him, not having a 
righteousness of my own that comes from the law, but that which is through faith in Christ – the 
righteousness that comes from God on the basis of faith. 
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Introduction: Nasopharyngeal (NP) colonization by Streptococcus pneumoniae (the 
pneumococcus) precedes the development of respiratory tract infection. Colonization by 
antimicrobial-resistant pneumococci, especially in infants, is a major public health concern as 
pneumococcus is a frequent cause of bacterial acute respiratory tract infections among 
children. This study longitudinally investigated antimicrobial resistance amongst 
pneumococci colonizing the nasopharynx of South African infants immunized with the 13-
valent pneumococcal conjugate vaccine (PCV13).  Furthermore, the study explored strain-
level pneumococcal colonization patterns and associated antimicrobial resistance 
determinants as well as the composition of the NP antibiotic resistome using shotgun 
metagenomic sequencing. 
Methods: NP swabs were collected every second week from birth through the first year of 
life from 137 infants who were immunized with 2+1 doses of PCV13. These were the first 
137 infants enrolled in the cohort who had the most complete fortnightly NP sampling 
(defined as at least 23-26 fortnightly collected NP swabs). Pneumococci were identified and 
serotyped using conventional techniques, and their antibiotic susceptibility profiles 
determined by disc diffusion and E-test. A subset of 196 NP samples from 23 infants were 
selected based on changes in serotype or antimicrobial resistance. These were subjected to 
broth enrichment, total nucleic acid extraction and subsequent shotgun metagenomic 
sequencing. Sequence reads were assembled and aligned to reference pneumococcal 
genomes. In-silico pneumococcal capsular, multilocus sequence typing, and antimicrobial 
resistance determinants were described. Finally, antibiotic resistance genes were identified 
from all bacterial contigs, to determine the NP resistome. 
Results: 1520 pneumococcal (760 non-duplicate) isolates were recovered from 137 infants; 
including non-typeable (n = 99), PCV13 (n = 133), and non-PCV13 serotypes (n = 528). The 
prevalence of penicillin, erythromycin, and cotrimoxazole non-susceptibility was 19% 
(147/760; 95% CI 17-22%) (3% resistant), 18% (136/760; 95% CI 15-21%) (14% resistant) 
and 45% (344/760; 95% CI 42-49%) (36% resistant), respectively. The predominant 
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penicillin-non-susceptible serotypes included 15B/15C (n = 20), 19A (n = 13), 15A (n = 10), 
19F (n = 8), and 21 (n = 8). Multi-drug resistance (MDR) was observed in 9% (68/760; 95% 
CI 7-11%) of the isolates. PCV13 serotypes were more likely to be non-susceptible, 
compared to non-PCV13 serotypes, to penicillin (26% vs. 16%, p = 0.007), erythromycin 
(23% vs. 15%, p = 0.027) and cotrimoxazole (62% vs. 41%, p < 0.001). Non-susceptibility to 
penicillin, erythromycin, and cotrimoxazole remained relatively constant through the first year 
of life (X2 test for trend: p = 0.184, range 0 – 25%; p = 0.171, range 0 – 27%; and p = 0.572, 
range 0 – 55%, respectively). Overall, penicillin or erythromycin-non-susceptible 
pneumococci were carried for a shorter duration than susceptible pneumococci (penicillin 
[mean days, 18 vs. 21, p = 0.013] and erythromycin [mean days, 18 vs. 21, p = 0.035]). 
Forty-five percentage (61/137) of infants carried the same serotype which acquired or lost 
resistance over time, and these changes were predominantly for penicillin (76%, 79/104). 
Of the 196 NP samples sequenced, 174 had corresponding positive cultures for 
pneumococci and, of these, 152 were assigned an in-silico serotype. Metagenomic 
sequencing detected a single pneumococcal serotype in 85% (129/152), and co-colonization 
in 15% (23/152) of NP samples, respectively. In total, 22 different pneumococcal serotypes 
were identified, with 15B/15C (n = 49) and 16F (n = 21) being the most common non-PCV13 
serotypes, while 23F (n = 9) and 19A (n = 8) were the most common PCV13 serotypes. 
Twenty-six different sequence types (STs), including 4 novel STs were identified. Mutations 
in the folA and folP genes, associated with cotrimoxazole resistance, were detected in 89% 
(87/98) of cotrimoxazole-non-susceptible pneumococci and mutations in the pbp1a and 
pbp2x genes, known to confer beta-lactam resistance, were identified in penicillin non-
susceptible ST705215B/15C isolates. A total of 329 antimicrobial resistance (AMR) genes were 
detected in 64% (125/196) of the sequenced samples, including 36 non-redundant genes 
ranging from 1 to 14 genes per sample. The predominant AMR genes detected were those 
conferring resistance to beta-lactams (52%, 172/329), macrolide-lincosamide-streptogramin 
(17%, 56/329), and tetracycline (12%, 38/329). The msrD, ermB, and mefA genes were only 
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detected from pneumococcal reads. The predominant resistance genes detected from non-
pneumococcal reads included blaOXA-60, blaOXA-22, and blaBRO-1. 
Conclusion: NP carriage of antibiotic-non-susceptible pneumococci was relatively constant 
throughout the first year of life. Despite high vaccine coverage levels, PCV13 serotypes were 
identified and were more commonly non-susceptible to penicillin, erythromycin, and 
cotrimoxazole. Overall, penicillin or erythromycin-non-susceptible pneumococci were carried 
for a shorter duration than susceptible pneumococci, however, non-susceptible PCV13 
serotypes were carried for a longer duration than non-susceptible non-PCV13 serotypes. 
Direct shotgun sequencing from enriched NP samples was shown to be a powerful 
technique for a detailed description of the pneumococcal component of the NP microbiome 
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1.1 General introduction 
Streptococcus pneumoniae (the pneumococcus) is a commensal that also causes 
diseases.1 Pneumococcus resides in the human nasopharynx where it can be carried 
asymptomatically and transmitted from person to person.2 It is a Gram-positive, alpha-
haemolytic facultative anaerobic bacterium,3 first identified simultaneously and 
independently by George Sternberg and Louis Pasteur in 1881.1 Pneumococcus is optochin-
sensitive which generally distinguishes it from viridans streptococci which are also alpha-
haemolytic; it can also be differentiated from other related species based on its sensitivity to 
lysis by bile using the bile solubility test.4 Pneumococci are classified by serotype, which is 
defined by an antigenically distinct polysaccharide capsule. The capsule biosynthesis is 
encoded by the capsular polysaccharide (cps) locus within the pneumococcal genome.  Due 
to  high levels of genetic diversity within the cps locus, there have been more than 100 
pneumococcal serotypes described thus far.5,6 
Nasopharyngeal (NP) carriage of antimicrobial-resistant pneumococci is more common in 
children than the elderly.7 Colonization by resistant pneumococcus, especially in children, is 
a significant problem worldwide, since NP carriage of pneumococci precedes the 
development of disease.2 Pneumococcus is a frequent cause of bacterial acute respiratory 
tract infections which are the leading cause of mortality among children.8 Penicillin has been 
the most commonly used drug in treating pneumococcal diseases, however, its widespread 
use has resulted in the development of penicillin-resistant pneumococci.9 This has led to the 
introduction of beta-lactams with extended spectrum of activity and other classes of 
antibiotics for the treatment of pneumococcal diseases; and due in part to high antibiotic 
selective pressure, pneumococci with resistance to various classes of antibiotics have 
emerged worldwide.10 
The introduction of the pneumococcal conjugate vaccines (PCVs), which only include a 
subset of serotypes, has successfully reduced the carriage and attributable disease caused 
by vaccine serotypes worldwide.11 This has however led to an increase in the carriage and 
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levels of disease caused by serotypes not targeted by the PCVs, a phenomenon known as 
serotype replacement.11,12 PCVs have significantly reduced overall antibiotic resistance 
among pneumococci by targeting serotypes included in the vaccine which are commonly 
resistant to various antibiotics.13,14 However, there has been an increase in resistance 
among serotypes not included in the vaccine.15 NP colonization with antibiotic-resistant 
pneumococci is therefore concerning as this may lead to the development of pneumococcal 
diseases which are hard to treat with first-line antibiotics.16 
NP colonization by antibiotic-resistant pneumococci among children has continuously 
increased over the years.17 Despite this, there are limited data in the currently available 
literature on the NP carriage of resistant pneumococci among infants in early life and the 
prevalence of resistance is likely to be underestimated especially in low income community 
settings where there are limited resources and poor active surveillance.18 Additionally, there 
are no longitudinal cohort studies describing antimicrobial resistance among pneumococci in 
early life; therefore, there is a need for community-based studies to better understand the 
resistance patterns among pneumococci circulating in the community. 
1.2 Thesis outline 
This study describes the NP carriage of pneumococci including antimicrobial-resistant 
pneumococci among PCV13-vaccinated children participating in a South African birth cohort 
study. In addition, the study describes the use of a novel approach to studying 
pneumococcal NP colonization dynamics and antimicrobial resistance, using shotgun 
metagenomic sequencing. Furthermore, this study investigated the composition of the NP 
antibiotic resistome in Streptococcus-enriched samples in a South African longitudinal birth 
cohort. 
Chapter 2: Asymptomatic NP colonization is an important step for the development of 
pneumococcal diseases and also a reservoir for person-to-person transmission of antibiotic-
resistant pneumococci circulating in the community. To better understand the global 
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distribution and emergence of antibiotic-non-susceptible pneumococci, a review of the 
literature was conducted, reporting on the proportion as well as the mechanisms of 
resistance in pneumococci. This chapter presents a systematic review describing the global 
distribution of antibiotic-non-susceptible pneumococci colonizing the nasopharynx of 
apparently healthy children ≤12 years of age. This chapter summarizes the data on the 
proportions of antibiotic-non-susceptible pneumococci, with focus on the most commonly 
used antibiotics for treatment of pneumococcal infections. Chapter 2 also describes the 
identified limitations of the currently available data and highlights areas which need further 
research. 
Chapter 3: Pneumococcus is an important bacterial cause of pneumonia among children, 
therefore, NP colonization with antimicrobial-resistant pneumococci is of major public health 
concern because pneumococcal diseases are preceded by NP colonization. To better 
understand pneumococcal resistance patterns, among carriage isolates, we used culture-
based methods to investigate antimicrobial resistance amongst pneumococci colonizing the 
nasopharynx of 137 vaccinated South African infants during the first year of life. This chapter 
describes the penicillin, erythromycin, and cotrimoxazole resistance patterns among 
pneumococci, as well as the trends of resistance over time.   
Chapter 4: Pneumococci are most commonly identified using bacterial culture followed by 
both phenotypic and genotypic characterization of the isolates. Individuals may be colonized 
by multiple different serotypes at the same time, but currently used methods are unable to 
provide a detailed characterization of strain-level pneumococcal colonization. We used 
shotgun metagenomic sequencing, a novel approach, to study pneumococcal NP 
colonization dynamics and antimicrobial resistance determinants. This chapter describes the 
pneumococcal component of the NP microbiota, including colonization with multiple 
pneumococcal serotypes and genetic resistance determinants. 
Chapter 5: The nasopharynx is a reservoir for many respiratory pathogens including 
pneumococcus, and may also serve as a source for the transfer of antimicrobial resistance 
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genes from non-pathogenic to pathogenic bacteria. Culture-based methods are unable to 
comprehensively characterize the antibiotic resistome of the NP microbiota. As a 
continuation of chapter 4, we investigated the composition of the NP antibiotic resistome, 
using shotgun metagenomic sequencing. This chapter therefore describes the NP antibiotic 
resistome (pneumococcal and non-pneumococcal resistomes). 
Chapter 6: This section presents the general conclusions of the investigations conducted in 
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Antimicrobial resistance in Streptococcus pneumoniae (the pneumococcus) is a growing 
public health concern. Nasopharyngeal (NP) colonization with antibiotic-non-susceptible 
pneumococcus (ANSP) is therefore of importance, since the NP is the major reservoir for 
transmission of pneumococci and facilitates exchange of antibiotic resistance genes. This 
systematic review summarizes data on the global distribution of antimicrobial resistance in 
pneumococci colonizing the nasopharynx of healthy children. A literature search was 
conducted in PubMed, Scopus, Web of Science, and EBSCOhost to identify articles 
reporting on ANSP in the nasopharynx of apparently healthy children ≤12 years old. We only 
included articles published in English up to 30 April 2018. Ninety studies were included and 
analysed. Most of these studies were conducted in Europe (41%, 37/90), followed by Asia 
(31%, 28/90), Africa (12%, 11/90), South America (8%, 7/90), North America (6%, 5/90), and 
Australia/Oceania (2%, 2/90). Non-susceptibility to penicillin and cotrimoxazole were high in 
studies from Asia and Africa. Cefotaxime-non-susceptibility was uncommon in most 
countries except in South Korea and China. Levofloxacin non-susceptibility was very rare. 
Few studies (n = 9) reported the genetic resistance determinants in pneumococci, and ermB 
was the most commonly described gene in those studies.  Although there are limited data on 
the carriage of resistant pneumococci in children from developing countries, this review 
showed that resistant pneumococci have a worldwide distribution. There is a need to 
conduct further studies to monitor the trends of resistance and this should be coupled with 









Streptococcus pneumoniae (the pneumococcus) is a major cause of morbidity and mortality 
in young children and adults worldwide. Those at the extremes of age are particularly 
vulnerable to life-threatening invasive diseases including pneumonia, sepsis and 
meningitis.1–4 The treatment of pneumococcal disease has traditionally relied on beta-
lactams and macrolides, however, resistance to these agents is increasing globally.5,6 
Increasingly, antibiotic resistance poses a threat to the effective treatment of pneumococcal 
infections. Emerging antimicrobial resistance is exacerbated by excessive use of 
antimicrobial therapy in primary care, particularly in children.7,8 
Asymptomatic NP colonization by pneumococci precedes invasive disease and is a reservoir 
for community transmission of drug-resistant pneumococci.9,10 To better understand the 
global distribution and potential for emergence of antibiotic-non-susceptible pneumococcus 
(ANSP) infections, we conducted a review of the currently available literature, reporting on 
the proportion and/or underlying mechanisms of resistance in pneumococci carried in the NP 
of apparently healthy children. 
2.2 Methods 
2.2.1 Eligibility criteria 
Peer-reviewed articles reporting on antibiotic susceptibility profiles among pneumococci in 
the nasopharynx of children ≤12 years, published in English prior to 30 April 2018, were 
considered. Studies that enrolled children who were reported to be healthy, or had no 
reported underlying illness at the time of enrolment were included. NP samples included 
specimens obtained from the nasopharynx, with a sterile swab or by NP aspiration. Studies 
where there was no clear differentiation of illness, sample type, age, or antibiotic 
susceptibility results were excluded. Reviews, clinical trials and intervention studies were 
also excluded. References from reviews and included studies were not checked for eligibility. 
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A literature search was conducted in PubMed, Scopus, Web of Science and EBSCOhost for 
published articles using the keywords in Table 2.1. The search strategy was designed to 
include all studies reporting on any antibiotic-non-susceptible bacteria colonizing the 
nasopharynx of children. There was no limit on publication year.  
Table 2.1: Keywords search 






Until 30 April 
2018 
(neonat* OR infant* OR child* OR baby OR babies) AND 
(nasopharyn*) AND (bacteria* OR bacterium OR pathogen* 
OR microb*) AND (antibiotic* OR antimicrobial* OR drug*) 
AND (resistome OR resistan* OR non-susceptib* OR 
nonsusceptib* OR non susceptib*) NOT (fungi OR fungus OR 
fungal OR virus OR viral OR parasite OR parasitic OR 
parasites) 
Scopus  Until 30 April 
2018 
(neonat* OR infant* OR child* OR baby OR babies) AND 
(nasopharyn*) AND (bacteria* OR bacterium OR pathogen* 
OR microb*) AND (antibiotic* OR antimicrobial* OR drug*) 
AND (resistome OR resistan* OR non-susceptib* OR 
nonsusceptib*)  
*(Academic Search Premier, Africa-Wide Information, and CINAHL) 
 
2.2.2 Data analysis 
Studies meeting the inclusion criteria were reviewed by two independent reviewers, data 
were extracted and summarized (the student conducted the systematic review and was 
responsible for data analyses and write-up, however, a second independent reviewer was 
required to go through the same process of selecting articles using the defined criteria thus 
avoiding biases). The following information was extracted: the year and country in which the 
study was conducted, age group of the participants, methods used to determine antibiotic 
susceptibility profiles, categorical antibiotic susceptibility data, and antibiotic resistance 
genes. The proportion of ANSP was calculated based on the total number of isolates tested 
in each of the eligible studies. Penicillin, cefotaxime, erythromycin, tetracycline, 
cotrimoxazole, ciprofloxacin, levofloxacin, and chloramphenicol susceptibility data were 
extracted. Non-meningitis breakpoints were considered in studies that used both non-
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meningitis and meningitis breakpoints for interpretation of penicillin and cefotaxime 
susceptibilities. Resistant and intermediate isolates were collectively regarded as non-
susceptible. Multi-drug resistance (MDR) was defined as non-susceptibility to three or more 
classes of antibiotics. 
2.3 Results 
2.3.1 Study selection 
A total of 2133 articles were identified from the four databases: PubMed (n = 91), Scopus (n 
= 372), Web of Science (n = 732) and EBSCOhost (n = 938). After removing duplicates, the 
titles and abstracts of 2072 articles were screened for inclusion. Of 2072 articles screened, 
1680 did not meet the specified inclusion criteria and were subsequently excluded. Of the 
remaining 392 full-text articles assessed for eligibility, 90 full-text articles were included in 
this review. A PRISMA flow diagram of studies reviewed is shown in Figure 2.1.  
 
Figure 2.1: Flow diagram showing selection of studies reviewed according to Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis. 
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2.3.2 Study characteristics 
A summary of articles included is shown in Tables 2.2, 2.3 and 2.4. Ninety studies (80 cross-
sectional and 10 repeated cross-sectional studies) conducted in 44 countries were included. 
The majority of the studies originated from Europe (41%, 37/90), followed by Asia (31%, 
28/90), Africa (12%, 11/90), South America (8%, 7/90), North America (6%, 5/90), and 
Australia/Oceania (2%, 2/90). All 90 studies were conducted between 1990 and 2015: 30 
studies (1990-1999), 38 studies (2000-2009), and 18 studies (2010-2015). The year of study 
was not reported in four studies. 
The age group of participants included ranged from 0-120 months (Tables 2.2 and 2.3). The 
extracted data could not be stratified according to age since age grouping was reported as 
overlapping age ranges. Sample collection procedures were described in 94% (85/90) of the 
studies. NP samples were obtained using sterile swabs (n = 82), NP aspiration (n = 2), or 
using both techniques (n = 1) (data not shown). The methods used to determine 
antimicrobial susceptibility patterns were reported in 99% (89/90) of the studies, with E-test 
being the most commonly used (71%, 63/89). E-test was used alone in 18% (16/89) of the 
studies, and in combination with disc diffusion and agar dilution in 52% (46/89) and 1% 
(1/89) of the studies, respectively. Susceptibility breakpoints used for interpretation of the 
results were described in 94% (85/90) of the studies; Clinical Laboratory Standards Institute 
(CLSI) breakpoints were most commonly used (87%, 74/85) (data not shown).  
2.3.3 Distribution of ANSP 
The proportion of ANSP isolated from the NP of healthy children reported from each study is 
shown in Tables 2.2 and 2.3. The distribution of the overall proportion of penicillin, 
erythromycin, and cotrimoxazole-non-susceptible pneumococci by country is shown in 
Figures 2.2, 2.3, and 2.4, respectively. 
2.3.3.1 Non-susceptibility to beta-lactams 
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The proportion of penicillin-non-susceptible Streptococcus pneumoniae (PNSP) differed 
substantially between countries and regions. The proportions of PNSP exceeded 80% in 
studies in Kenya, Uganda, South Korea, and Taiwan, but were lower than 2% in Norway 
(Tables 2.2 and 2.3). Three South Korean studies in 2008 (92%),11  2009-2010 (95%),12 and 
2010 (91%),13 reported the highest proportions of PNSP. Low proportions of PNSP were 
mainly reported in India (Table 2.2), ranging from 0% in 1994-1995,14 to 17% in 2010-2013.15 
No PNSP were reported in two studies in Indonesia in 1997,16 and in England in 2003.17 
Cefotaxime-non-susceptible pneumococci were uncommon, with proportions less than 10% 
reported mainly in European and African countries (Table 2.2 and 2.3). However, the 
proportions of cefotaxime-non-susceptible pneumococci were high in China in 1999-2000 
(43%),18 and Korea in 2014 (31%).19  
Repeated cross-sectional studies from 8 countries reported varying changes in penicillin or 
cefotaxime non-susceptibility over time (Table 2.3). There was an increase in the proportions 
of PNSP in studies conducted in Greece (12% in 2000 to 29% in 2003,20 and 20% in 2005 to 
35% in 2009),21 Singapore (28% in 1998, to 70% in 2007-2008),22 and Israel (33% in 1993 to 
77% in 1994).23 In other studies, the change in the proportions of PNSP over time were 
minimal including in Iceland (11% in 2009-2012 to 10% in 2013-2015),24 Norway (1.7% in 
2006 to 1.9% in 2008),25 and Portugal (24% in 2001 to 22% in 2006).26 Only one study, 
conducted in the USA, reported a notable decrease in the proportions of PNSP (44% in 
2006-2010 to 32% in 2010-2015) and cefotaxime-non-susceptible pneumococci over time 
(16% in 2006-2010 to 7% in 2010-2015).27  
2.3.3.2 Non-susceptibility to macrolides 
The highest proportions of erythromycin-non-susceptible pneumococci were described in 
studies in China, South Korea, and Taiwan (Table 2.2). Four studies in China reported high 
proportions of erythromycin-non-susceptible pneumococci: 1997-1998 (99%),28 1999-2000 
(77%),18 2012 (51%),29 and 2013-2014 (80%), respectively.30 Three South Korean studies 
conducted in 2008 (85%),11 2009-2010 (93%),12 and 2014 (91%),19 as well as one study in 
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Taiwan (87%),31 also reported high erythromycin-non-susceptible pneumococci. High 
proportions of erythromycin-non-susceptibility were also reported in non-Asian countries 
including in Italy (64% in 1995-1996,32 61% in 1996-1997,33 and 60% in 1997),34 Portugal 
(69% in 1997-2003),35 Belgium (62% in 2000-2001),36 and Morocco (62% in 2007-2009).37 
Three studies in Africa, one from Lesotho,38 and two from Uganda,39,40 did not detect any 
erythromycin-non-susceptible pneumococci. Repeated cross-sectional studies in Portugal 
(26% in 2001 to 24% in 2006),26 Norway (6% in 2006 to 3% in 2008),25 the USA (30% in 
2006-2010 to 16% in 2010-2015),27 and Iceland (13% in 2009-2012 to 9% in 2013-2015),24 
showed a decrease in the proportions of erythromycin non-susceptibility over time. 
2.3.3.3 Non-susceptibility to cotrimoxazole 
Studies in Asia, Africa, and South America reported the highest overall proportions of 
cotrimoxazole non-susceptible pneumococci (Figure 2.4). Four studies in Kenya in 2009-
2010 (99%),41 Uganda in 1995 and 2008 (85%,39 and 99%,40 respectively), and Tanzania in 
2010 (83%),42 reported the highest proportions of cotrimoxazole-non-susceptibility on the 
African continent (Figure 2.4). Non-susceptibility to cotrimoxazole was also common in Asia 
with proportions over 65% reported in India, Iran, South Korea, Taiwan, and China (Table 
2.2). Studies in India recorded high proportions of cotrimoxazole-non-susceptible 
pneumococci: 81% in 1998-1999,43 82% in 2000-2002,44 53% in 2004,45 91% in 2010-
2011,15 and 78% in 2012-2013.46 Repeated cross-sectional studies reported a notable drop 
in the proportions of cotrimoxazole-non-susceptibility over time: in Portugal (26% in 2001 to 
12% in 2006),26 Norway (5% in 2006 to 2% in 2008),25 the USA (27% in 2006-2010 to 13% 
in 2010-2015),27 and Iceland (22% in 2009-2012 to 12% in 2013-2015).24  
2.3.3.4 Non-susceptibility to fluoroquinolones 
Reports on ciprofloxacin or levofloxacin susceptibility were uncommon. Among ten studies 
that reported ciprofloxacin susceptibility, five studies in Bulgaria (in 1999),47 China (in 1999-
2000),18 Russia (in 2001-2002),48 Greece (in 2005-2009),49 and Turkey (year not specified),50 
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reported the proportion of ciprofloxacin non-susceptibility of less than 2%. Alarming 
proportions of ciprofloxacin-non-susceptible pneumococci were reported in Morocco (71%),37 
and Greece (51%),51 in 2007-2009 and 2010-2012, respectively. Non-susceptibility to 
levofloxacin was rare; no levofloxacin-non-susceptible pneumococci were detected in 18 out 
of 25 studies that reported results (Table 2.2). Seven studies in Singapore (2% in 2007-
2008),22 Senegal (2% in 2007-2008),52 South Korea (1% in 2009-2010),12 Greece (1% in 
2010-2012),51 India (2% in 2012-2013),46 and Egypt (4% in 2013-2014),53 and South Korea 
(1% in 2014),19 reported low proportions of levofloxacin-non-susceptible pneumococci. 
2.3.3.5 Non-susceptibility to other antibiotics 
Similar to cotrimoxazole-non-susceptibility, high proportions of non-susceptibility to 
tetracycline of over 65% were reported in studies conducted in Taiwan (97%),31 China (99% 
in 1997-1998),28 and South Korea (89% in 2009-2010,12 and 79% in 2014).19 
Chloramphenicol susceptibility was not determined in many studies included in this review 
(Tables 2.2 and 2.3). However, the proportions of chloramphenicol-non-susceptible 
pneumococci exceeding 30% were only reported in Italy (34% in 1997),34 China (34% in 
1999-2000),18 Taiwan (42%),31 Morocco (38% in 2007-2009),37 and South Korea (38% in 
2009-2010).12  
2.3.3.6 Multi-drug resistant pneumococci 
Data on the proportions of MDR were available in 52 of the 90 studies included in this 
review; three studies in South Korea recorded the highest proportions of MDR (62% in 
2008,11 92% in 2009-2010,12 and 82% in 2014).19 High proportions of MDR were also 
reported in other Asian countries including in China in 1999-2000 (39%),18 Singapore in 
2007-2008 (75%),22 India in 2012-2013 (51%),46 and Taiwan (87%).31  Studies in Africa and 
southern Europe also reported high proportions of MDR: in Italy in 1996-1997 and 1997 
(45%,33 and 53%,34 respectively), Turkey 2007-2008 (50%),54 Morocco 2007-2009 (43%),37 
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and Egypt in 2013-2014 (41%).53 MDR proportions were low in Norway in 2006 and 2008 
(3%,55 and 1%,25 respectively).  
2.3.4 Antimicrobial resistance determinants  
Ten percent (9/90) of the studies reported testing for genetic resistance determinants using 
targeted PCR (Table 2.4). The ermB gene was the most commonly detected macrolide-
resistance gene among macrolide-non-susceptible pneumococci, followed by mefA and 
mefE genes (Table 2.4). In an Italian study, pneumococci carrying the ermB gene were 
resistant to both erythromycin and clindamycin whereas those harbouring mefA had low 
level (intermediate) of resistance to erythromycin.56 Another Italian study showed that all 82 












Figure 2.2. Distribution of the overall proportion of penicillin-non-susceptible pneumococci (%), by country, in the NP of apparently healthy children younger 
than 12 years of age (included eligible studies until 30 April 2018). Note: the map does not represent national surveillance data and does not take into 













Figure 2.3. Distribution of the overall proportion of erythromycin-non-susceptible pneumococci (%), by country, in the NP of apparently healthy children 
younger than 12 years of age (included eligible studies until 30 April 2018). Note: the map does not represent national surveillance data and does not take 













Figure 2.4. Distribution of the overall proportion of cotrimoxazole-non-susceptible pneumococci (%), by country, in the NP of apparently healthy children 
younger than 12 years of age (included eligible studies until 30 April 2018). Note: the map does not represent national surveillance data and does not take 
into account the temporal variation in antibiotic-resistant pneumococci. 
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AST methods MDR 
Antibiotic, no. of non-susceptible isolates (% of non-susceptible isolates) 
PEN CTX ERY TET SXT CIP LVX CHL 
Africa             
Côte d’Ivoire57 1997-98 3-60 E-test/DD 13 (9) 11 (8) 3 (2) 16 (12) 79 (57) 72 (52) - - 4 (3) 
Egypt53 2013-14 2-60 Broth/DD 41 (41) 15 (15) 1 (1) 43 (43) 55 (55) 62 (62) - 4 (4) 0 
Ghana58 2011 ≤72 E-test/DD - 13 (46) - - - - - - - 
Kenya41 2009, 2010 <60 Broth 105 (16) 515 (82) - 8 (1) 122 (19) 619 (99) - 0 12 (2) 
Lesotho38 1995-96 <60 E-test/DD - 11 (4) - 0 6 (2) 17 (6) - - 2 (1) 
Morocco37 2007-09 1-24 E-test/DD 65 (43) 58 (39) 11 (7) 93 (62) 75 (50) 86 (57) 106 (71) 0 57 (38) 
Niger59 2007-08 0-24 E-test/DD - 23 (11) - 9 (4) 148 (71) - -  24 (11) 
Senegal52 2007-08 0-24 DD/Agar - 20 (15) 1 (1) - - - 32 (24) 3 (2) - 
Tanzania42 2010 <60 E-test/DD 19 (17) 78 (68) - 7 (6) 12 (10) 95 (83) - - 4 (4) 
Uganda39 1995 0-36 DD/Agar  32 (28) 96 (84) 0 0 37 (32) 98 (85) - - 12 (10) 
Uganda40 2008 2-59 E-test/DD - 72 (81) - 0 - 88 (99) - - - 
Asia             
China28 1997-98 <60 E-test/Agar  - 42 (40) - 103 (99) 103 (99) 90 (87) - - 30 (29) 
China18 1999-00 24-72 E-test/DD 151 (39) 223 (58) 164 (43) 295 (77) - 309 (81) 0 0 129 (34) 
China29 2012 12-18 E-test - 6 (6) - 52 (51) - - - 0 - 
China30 2013-14 2-18 Broth 8 (10) 6 (7) 11 (13) 67 (80) - - - - - 
India60 - 3-36 E-test/DD 2 (15) 2 (15) 0 1 (8) - 13 (100) 2 (15) - - 
India14 1994-95 0-18 DD - 0 - 5 (3) - 11 (5) - - 13 (6) 
India43 1998-99 2-6 DD 3 (1) 11 (3) - 120 (37) - 262 (81) - - - 
India44 2000-02 60-120 DD 194 (15) 42 (3) - 140 (11) 782 (61) 1053 (82) - - 137 (11) 
India45 2004 72-120 - - 43 (6) 35 (6) 5 (1) 230 (30) 413 (53) - - 12 (2) 
India15 2010-11 3-60 E-test/DD 10 (19) 9 (17) 2 (4) 5 (10) 19 (36) 48 (916) 5 (9) - - 
India46 2012-13 6-50 E-test/DD 23 (51) 5 (11) - 22 (49) 19 (42) 35 (78) - 1 (2) 6 (13) 
Indonesia16 1997 0-25 E-test/DD - 0 - - - 20 (9) - - 13 (6) 
Iran61 2013-14 6-72 DD - - 0 42 (57) 45 (61) 69 (93) - 0 12 (16) 
Israel62 1996-97 12-35 E-test/DD 65 (11) 256 (43) - - - - - - - 
Japan63 1999 1-60 E-test/DD - 57 (61) - - - - - - - 
Jordan64 2012-13 1-60 E-test/DD - - - 31 (59) - 36 (68) - 0 0 
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AST methods MDR 
Antibiotic, no. of non-susceptible isolates (% of non-susceptible isolates) 
PEN CTX ERY TET SXT CIP LVX CHL 
South Korea11 2008 18-59 Broth 58 (62 86 (92) - 80 (85) - - - - - 
South Korea12 2009-10 <60 E-test 139 (92) 144 (95) 24 (16) 140 (93) 134 (89) 98 (65) - 1 (1) 57 (38) 
South Korea13 2010 6-60 Broth - 122 (91) - - - - - - - 
South Korea19 2014 6-71 E-test 181 (82) 191 (86) 68 (31) 201 (91) 176 (79) 108 (49) - 2 (1) 66 (30) 
Palestine65 2012-13 1-23 E-test/DD 72 (34) 141 (67) 0 64 (30) - 97 (46) - -  
Russia48 - <84 E-test 6 (2) 23 (8) - 14 (5) - 163 (53) - - - 
Russia66 2001-02 <60 Broth 195 (10) 397 (19) 18 (1) 143 (7) 1070 (52) 1327 (65) 35 (2) 0 - 
Taiwan31 - 48-78 Broth 27 (87) 27 (87) 2 (7) 27 (87) 30 (97) 28 (90) - 0 13 (42) 
Europe             
Bulgaria47 1999 12-72 DD 19 (22) 19 (22) 0 18 (21) 32 (38) 36 (42) 0 - 9 (11) 
Belgium36 2000-01 3-36 E-test/DD - 14 (14) - 61 (62) 48 (49) - - - - 
Czech Republic67 2004-05 36-72 Broth - 5 (3) 0 2 (1) 9 (6) 26 (16) - - 9 (6) 
Cyprus68 2013-14 6-36 E-test/DD 37 (13) 78 (28) 10 (4) 79 (28) 41 (15) 68 (24) - - 0 
England17 2003 6-60 DD - 0 - 21 (185) 9 (8) - - - - 
Estonia69 1999-00 24-84 DD - 16 (9) - 7 (4) 62 (34) 130 (71) - - - 
Estonia70 1999-00,03 12-84 E-test/DD 14 (4) 18 (6) - 18 (6) - 200 (67) - - - 
France71 2006-09 6-24 Agar - 85 (32) - - - - - - - 
Greece72 1995-96 12-73 E-test/DD 41 (31) 38 (29) 16 (12) 25 (19) 39 (29) 58 (43) - - 36 (27) 
Greece73 1997 8-74 E-test/DD 15 (11) 13 (10) - 18 (14) 15 (11) 30 (23) - - 11 (8) 
Greece74 1997-98 2-23 E-test/DD - 70 (17) 24 (6) 79 (19) 72 (17) 76 (18) - - 52 (12) 
Greece 75 1997-99 2-23 E-test/DD 110 (14) 122 (16) - 137 (18) 136 (17) 151 (19) - - 86 (11) 
Greece76 2000-04 30-54 E-test - 20 (12) 0 32 (19) - 12 (7) - - - 
Greece49 2005-09 13-76 E-test/DD - 229 (87) - 263 (24) 158 (60) 174 (66) 0 0 42 (16) 
Greece51 2010-12 21-78 E-test 32 (22) 43 (29) 0 42 (28) 3 (2) 45 (30) 76 (51) 1 (1) 0 
Iceland77 1999 14-76 E-test/DD - 30 (7) - 25 (6) 62 (15) 181 (45) - - 31 (8) 
Iceland78 2009 14-76 E-test/DD - 58 (15) - - - - - - - 
Italy32 1995,96 8-36 DD - 11 (21) 3 (6) 34 (64) 17 (32.1) 34 (64) - - 2 (4) 
Italy33 1996-97 - E-test/DD 77 (45) 22 (13)  106 (61) 82 (47.4) - - - - 
Italy34 1997 36-60 E-test/DD 64 (53) 17 (14) 1 (1) 73 (60) 66 (54.5) 89 (73) - - 41 (34) 
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AST methods MDR 
Antibiotic, no. of non-susceptible isolates (% of non-susceptible isolates) 
PEN CTX ERY TET SXT CIP LVX CHL 
Italy56 1999 2-65 E-test - 16 (19) 1 (1) 44 (52) 41 (48) 43 (51) - - 4 (5) 
Italy79 2011 3-59 E-test 58 (17) 106 (31) - 122 (36) 100 (29) 50 (15) - 0 6 (2) 
Italy80 2011-12 0-60 E-test - 56 (30) - 78 (42) 68 (37) - - - 3 (2) 
Norway55 2006 10-69 E-test 14 (3) 9 (2) - 30 (6) 28 (6) 67 (13) - - - 
Portugal81 1996 6-72 E-test/DD - 66 (24) - 46 (17) 61 (22) 92 (33) - - 22 (8) 
Portugal35 1997-03 - E-test/DD - 177 (83) - 146 (69) 141 (66) 155 (73) - - 0 
Portugal82 2007 6-72 E-test/DD - 48 (16) 2 (1) 48 (16) 35 (12) 31 (10) - 0 4 (1) 
Sweden83 2004-05 13-24 DD - 12 (4) - 13 (4) 16 (5) 29 (10) - - - 
Turkey50 - 72-120 Agar - 24 (25) 26 (27) 40 (42) 39 (41) 51 (53) 1 (1) - - 
Turkey84 2004 0-67 E-test/DD 20 (18) 44 (39) - 18 (16) 18 (16) 51 (46) - -  
Turkey85 2004-05 12-72 DD - 7 (28) - 1 (4) 2 (8) 5 (20) - - - 
Turkey54 2007-08 12-59 E-test/DD 15 (50) 26 (87) - 12 (40) 10 (33) 19 (63) - 0 4 (13) 
Turkey86 2012 48-72 E-test/DD - 3 (50) - - - - - - - 
North America             
Guatemala87 2001-06 5-60 E-test 113 (20) 149 (27) 18 (3) 155 (28) - 347 (63) - - - 
Mexico88 2002 2-72 Broth - 528 (64) - - - - - - - 
USA89 1998 ≤96 E-test 19 (14) 35 (25) - 19 (14) - 39 (28) - - - 
USA90 1998-99 ≤60 E-test/DD - 3 (6) - 2 (4) 0 9 (19) - - - 
South America             
Brazil91 2005 2-59 E-test/DD 170 (25) 178 (26) - 9 (6) 15 (11) 116 (82) - 0 20 (14) 
Brazil92 2008 3-72 E-test/DD 9 (10) 32 (35) - 8 (9) 6 (6) 67 (73) - 0 1 (1) 
Brazil93 2008-09 1-59 Broth 27 (7) 153 (38) 8 (2) 12 (3) 74 (19) 231 (58) - - - 
Brazil94 2010 <72 E-test/DD - 33 (27) - 2 (2) 2 (2) 62 (51) - 0 4 (3) 
Peru95 2000 3-38 E-test 9 (6) 22 (15) - 10 (7) - 83 (57) - - 3 (2) 
Venezuela96 2004-05 0-72 DD 8 (5) 21 (13) - 16 (10) 12 (8) - - 0 - 
Australia/Oceania             
Australia97 1997 <48 E-test/DD 172 (17) 256 (25) - 176 (17) 175 (17) 468 (46) - - 139 (14) 
Fiji98 2003-04 3-13 E-test/DD 3 (1) 28 (11) - 4 (2) - 50 (20) - - 0 
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Ref- Reference, AST- Antibiotic susceptibility testing, MDR- Multi-drug resistance, PEN- Penicillin, CTX- Cefotaxime, ERY- Erythromycin, TET- Tetracycline, SXT- 
Cotrimoxazole, CIP- Ciprofloxacin, LVX- Levofloxacin, CHL- Chloramphenicol, * AST data available for non-PCV7 serotypes only. CLSI- Clinical Laboratory Standards Institute, 
CASFM- Committee of the Antibiogram of the French Society of Microbiology, EUCAST- European Committee on Antimicrobial Susceptibility Testing, BSAC- British Society for 

























AST methods MDR 
Antibiotic, no. of non-susceptible isolates (% of non-susceptible isolates) 
PEN CTX ERY TET SXT CIP LVX CHL 
Asia             
Israel23 1993 6-42 E-test/DD 42 (15) 91 (33) - 44 (16) 44 (16)  96 (34) - - - 
 1994 6-17 E-test/DD 9 (11) 63 (77) - 9 (11) 9 (11) 66 (81) - - - 
Singapore22 1998 17-78 E-test/DD 34 (33) 28 (28) 18 (18) 34 (33) 49 (48) - - - - 
 2007-08 4-103 E-test/DD 44 (75) 41 (70) 4 (7) 46 (78) 40 (68) 39 (66) - 1 (2)  
Europe             
Greece20 2000 12-72 E-test - 77 (20) - 89 (23) - - - - - 
 2003 12-72 E-test - 160 (35) - 140 (31) - - - - - 
Greece99 2000 12-72 E-test 3 (1) 31 (8) - 89 (23) - - - - - 
 2003 12-72 E-test 77 (17) 106 (23) - 106 (30) - - - - - 
Greece*21 2005 13-76 E-test/DD 6 (3) 26 (12) 0 16 (8) 7 (3) 47 (22) - - 1 (1) 
 2006 13-76 E-test/DD 3 (3) 19 (18) 0 14 (13) 3 (3) 16 (15) - - 0 
 2007 13-76 E-test/DD 11 (5) 33 (15) 0 31 (14) 9 (4) 32 (14) - - 0 
 2009 13-76 E-test/DD 21 (8) 29 (29) 2 (1) 36 (14) 19 (7) 86 (32) - - 3 (1) 
Iceland24 2009-12 13-76 E-test/DD 82 (9) 97 (11) - 114 (13) 95 (11) 192 (22) - - - 
 2013-15 13-76 E-test/DD 16 (4) 38 (10) - 33 (9) 31 (9) 44 (12) - - - 
Norway25 2006 - E-test 24 (5) 9 (2) - 32 (6) 32 (6) 25 (5) - - - 
 2008 - E-test 8 (1) 11 (2) - 18 (3) 38 (7) 11 (2) - - - 
Portugal26 2001 4-72 E-test/DD  114 (25) 110 (24) - 122 (26) 107 (23) 119 (26) - 0 35 (8) 
 2006 4-72 E-test/DD 80 (20) 86 (22) - 93 (24) 72 (18) 47 (12) - 0 1 (0) 
North America             
USA27 2006-10 6-30 Vitek 2 22 (11) 93 (44) 33 (16) 63 (30) 40 (19) 56 (27) - 0 3 (1) 
 2010-15 6-30 Vitek 2 12 (3) 138 (32) 29 (7) 69 (16) 26 (6) 56 (13) - 0 0 
South America             
Peru100 1996-7 6-24 E-test/DD 6 (8) 4 (5) - 14 (19) - 39 (52) - - 17 (23) 
 2001 6-24 E-test/DD 17 (23) 15 (20) - 12 (16) - 55 (73) - - 20 (27) 
 2003 6-24 E-test/DD 10 (8) 40 (37) - 17 (14) - 74 (61) - - 13 (11) 
Ref- Reference, AST- Antibiotic susceptibility testing, MDR- Multi-drug resistance, PEN- Penicillin, CTX- Cefotaxime, ERY- Erythromycin, TET- Tetracycline, SXT- 
Cotrimoxazole, CIP- Ciprofloxacin, LVX- Levofloxacin, CHL- Chloramphenicol, * AST data available for non-PCV7 serotypes only. CLSI- Clinical Laboratory Standards 
26 
 
Institute, CASFM- Committee of the Antibiogram of the French Society of Microbiology, EUCAST- European Committee on Antimicrobial Susceptibility Testing, BSAC- British 
Society for Antimicrobial Chemotherapy, (-)- data not specific or missing, DD- Disc diffusion. 
 
 
Table 2.4. The distribution of antibiotic resistance genes by country. 
Country 
Number of isolates carrying resistance gene (percentage of isolates carrying resistance gene) 
Macrolides  Fluoroquinolones  Tetracycline 
erm(B) mef(A) mef(E) mef(A/E) L4# L22# 23S rRNA#  gyrA parC parE  tet(M) 
Russia66 46 (35) 40 (31) - - 30 (23) 3 (2) 2 (2)  1 (3) 6 (17) 19 (54)  - 
Jordan64 21 (40) - 20 (38) - - - -  - - -  - 
China28 100 (96)* - - 11 (11)* - - -  - - -  - 
Greece51 1 (2) 14 (30) - - - - -  - - -  - 
Greece75 93 (12) 40 (5) - - - - -  - - -  - 
Greece99 82 (39)** - - 127 (60) - - -  - - -  - 
Greece49 139 (53) 14 (5) 174 (66) - - - -  - - -  - 
Italy33 78 (45)* - 28 (16) - - - -  - - -  82 (47) 
Italy 56 40 (47) 4 (5) - - - - -  - - -  - 
# - Mutation in ribosomal proteins, * - erm or mef not characterized, ** - erm (AM)
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2.4 Discussion  
This review summarizes data on NP carriage of ANSP among apparently healthy children 
under the age of 12 years. There was marked variation in the proportion of resistance 
geographically. The proportions of pneumococci non-susceptible to penicillin and 
cotrimoxazole were greater than 50% in most studies conducted in Africa and Asia.  Studies 
conducted in Asia (South Korea, China, and Taiwan) also reported high proportions of MDR, 
erythromycin, and tetracycline-non-susceptible pneumococci. Cefotaxime non-susceptibility 
was uncommon in most countries, but with important exceptions in South Korea and China.  
Levofloxacin non-susceptibility was very rare.  
NP colonization by pneumococcus is a vital step for the development of respiratory tract 
infection.101 However, not all NP carriage isolates are associated with invasive disease but 
may approximate the proportions of antibiotic-non-susceptibility found in invasive isolates.102 
There was heterogeneity in the methods used to conduct studies included in this review 
which made comparison of the data from various studies difficult. Despite this limitation, 
some antibiotic-non-susceptibility trends were evident; the proportions of penicillin-non-
susceptible pneumococci were high in studies conducted in Asia and Africa. 
Beta-lactams, including penicillin and cefotaxime, are the most commonly used antibiotics in 
treating pneumococcal infections.6 Beta-lactam resistance may result in pneumococcal 
infection treatment failure; it is therefore important to evaluate the level of resistance to these 
drugs as infections with intermediate pneumococci may be treatable with higher doses.103 
Antibiotic non-susceptibility data could not be separated into intermediate and resistant due 
to inconsistency of data presentation in various studies and these were regarded as non-
susceptible.  
Erythromycin-non-susceptible pneumococci were not detected in two studies from Uganda, 
a country where penicillin and cotrimoxazole-non-susceptibility were high.39,40 These studies 
reported that erythromycin was the least frequently prescribed antibiotic among the 
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participants, which may explain the lack of resistance.39,40 Macrolides remain an alternative 
to beta-lactams for the treatment of pneumococcal infections.104 Similar to penicillin-non-
susceptibility, erythromycin-non-susceptibility was common in various studies included in the 
current review (Tables 2.2 and 2.3). High proportions of erythromycin-non-susceptibility in 
carriage pneumococcal isolates are concerning, especially in South Korea, Taiwan, China, 
Iran, Jordan, Belgium, and Morocco (Figure 2.3). To make any conclusions on the usage of 
erythromycin for pneumococcal diseases in these countries, sufficient surveillance data on 
invasive isolates are needed as macrolide resistance may be of limited clinical relevance in 
areas where beta-lactams remain effective.104  
Striking proportions of non-susceptibility to cotrimoxazole were described in studies 
conducted in Asian and African countries (Table 2.2 and Figure 2.4). Cotrimoxazole is a 
widely used antibiotic for the treatment of respiratory tract infections in many African and 
Asian countries.40,105 In several sub-Saharan countries, cotrimoxazole is used as a 
prophylaxis to prevent opportunistic infections in HIV-infected or exposed individuals, and its 
widespread use may drive cotrimoxazole resistance in this region.40,106 Therefore, resistance 
to cotrimoxazole needs further monitoring as this drug is also used, in many sub-Saharan 
countries, as first-line treatment for non-severe pneumonia.40 In India, the proportions of 
penicillin and erythromycin-non-susceptibility were very low but non-susceptibility to 
cotrimoxazole was high. A review from India has shown that cotrimoxazole is more readily 
available than beta-lactams or erythromycin; this may drive the emergence of cotrimoxazole 
resistance in this setting.105  
Studies from Asian countries reported the highest proportions of MDR compared to those in 
African and European countries. The emergence and spread of multi-drug-resistant 
pneumococci threaten the use of commonly prescribed antibiotics for pneumococcal 
infections as the carriage isolates are likely to cause invasive diseases.107 Fluoroquinolones, 
including levofloxacin, are recommended for the treatment of MDR pneumococcal 
infections.108 Resistance to levofloxacin has emerged but the proportions of non-
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susceptibility were low (Table 2.2 and 2.3). Further surveillance studies for monitoring 
levofloxacin resistance are warranted. 
There are limited longitudinal studies describing the NP pneumococcal antibiotic resistance 
patterns among children. This review only identified 10 repeated cross-sectional studies from 
eight countries (Table 2.3). Studies in Israel,23 Singapore,22 and Greece,20,21,99 reported an 
increase in the proportion of ANSP; this observation could be due to lack of vaccination as 
these studies were conducted between 1993 and 2008, a period where PCV was not 
available in many countries.109 In Israel, the rate of non-susceptibility to penicillin and 
cotrimoxazole was more than twice as high in 1994 as compared to 1993 and this was 
attributed to previous antibiotic exposure.23 Three studies in Greece that reported an 
increase in ANSP were conducted in two different regions, two in Athens metropolitan area 
(2000-2003)20,99 and one in central Greece (2005 -2009).21 Although there was an increase 
in non-susceptibility, temporal fluctuations in antibiotic non-susceptibility observed may be 
due to sampling of participants in various communities within Greece (not vaccine-induced 
as PCV7 was introduced in 2006).110 Serotypes included in the PCV are known to be highly 
resistant and the introduction of PCV has resulted in the reduction of resistance in PCV 
serotypes.111 A study conducted in the USA reported a notable decrease in the carriage of 
ANSP between 2006 and 2015 and this was likely due to the effects of PCV7.27  
Nine studies reported testing for genetic resistance determinants responsible for resistance 
(Table 2.4). For beta-lactam resistance, a combination of several penicillin-binding protein 
mutations is required to confer resistance to beta-lactams, this is complex, making it difficult 
to characterise all mutations responsible for resistance.112 ermB was the most commonly 
detected resistance gene among erythromycin-non-susceptible pneumococci; this gene 
confers resistance not only to macrolides but also to lincosamides and streptogramin B, 
characterized as the MLSB phenotype.113 ermB is associated with high-level resistance to 
both erythromycin and clindamycin whereas mef genes confer low or moderate levels of 
resistance to erythromycin but not clindamycin.114 The detection of tetM-mediated resistance 
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to tetracycline was only described in Italy.33 tetM, which encodes a protein blocking the 
binding of tetracyclines to the bacterial 30S ribosomal subunit, is the most common 
tetracycline resistance gene described in pneumococcal isolates.115  
Several limitations exist in the current review; the non-susceptibility data described were 
based on carriage isolates and cannot be used directly for treatment guidelines for invasive 
disease causing isolates. Studies included in this review used various antibiotic susceptibility 
testing methods, antibiotic panels and guidelines; for better comparison of resistance data 
from different countries, standardized methods for conducting surveillance studies are 
required. Antibiotic susceptibility data could not be linked to specific pneumococcal 
serotypes due to insufficient data reported in various studies. The design of the studies 
included in the review did not allow the evaluation of the impact of vaccines on the NP 
carriage of ANSP (there was insufficient data to tease this out and generate a significant 
analysis). This review did not evaluate the risk factors for carriage of resistant pneumococci, 
but studies reviewed here found that prior use of antibiotics, day-care attendance, winter 
season, and multiple physician visits were key risk factors.18,20,23,56,70,84  
Although there are limited data on the carriage of resistant pneumococci in children from 
developing countries, this review showed that resistant pneumococci have a worldwide 
distribution.116,117 Non-susceptibility to penicillin and cotrimoxazole were high in studies from 
Asia and Africa. To inform treatment guidelines and monitor the trends of resistance, routine 
and standardised surveillance studies for resistant NP carriage and invasive isolates are 
needed. To determine how resistance in pneumococci develops and spreads within regions, 
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Nasopharyngeal (NP) colonization by Streptococcus pneumoniae (pneumococcus) precedes 
the development of respiratory tract infection. Colonization by antimicrobial-resistant 
pneumococci, especially in infants, is a major public health concern. We longitudinally 
investigated antimicrobial resistance amongst pneumococci colonizing the nasopharynx of 
South African infants immunized with the 13-valent pneumococcal conjugate vaccine 
(PCV13). NP swabs were collected every second week from birth through the first year of life 
from 137 infants. Pneumococci were identified and serotyped using conventional 
microbiological techniques, and their antibiotic susceptibility profiles determined by disc 
diffusion and E-test. All infants were immunized with 3 doses of PCV13. 1520 pneumococcal 
(760 non-duplicate) isolates were recovered from 137 infants; including non-typeable (n = 
99), PCV13 (n = 133) and non-PCV13 serotypes (n = 528). The prevalence of penicillin, 
erythromycin, and cotrimoxazole non-susceptibility was 19% (147/760; 95% CI 17-22%) (3% 
resistant), 18% (136/760; 95% CI 15-21%) (14% resistant) and 45% (344/760; 95% CI 42-
49%) (36% resistant) respectively. The predominant penicillin-non-susceptible serotypes 
included 15B/15C (n = 20), 19A (n = 13), 15A (n = 10), 19F (n = 8), and 21 (n = 8). Multi-drug 
resistance (MDR) was observed in 9% (68/760; 95% CI 7-11%) of the isolates. PCV13 
serotypes were more likely to be non-susceptible, compared to non-PCV13 serotypes, to 
penicillin (26% vs. 16%, p = 0.007), erythromycin (23% vs. 15%, p = 0.027) and 
cotrimoxazole (62% vs. 41%, p < 0.001). Non-susceptibility to penicillin, erythromycin, and 
cotrimoxazole remained relatively constant through the first year of life (X2 test for trend: p = 
0.184, range 0 – 25%; p = 0.171, range 0 – 27%; and p = 0.572, range 0 – 55%, 
respectively). Overall, penicillin or erythromycin-non-susceptible pneumococci were carried 
for a shorter duration than susceptible pneumococci (penicillin [mean days, 18 vs. 21, p = 
0.013] and erythromycin [mean days, 18 vs. 21, p = 0.035]). Within individual infants carrying 
the same serotype longitudinally, changes in antibiotic susceptibility were observed over time 
in 45% (61/137) of infants and these changes were predominantly for penicillin (76%, 
79/104). Prevalence of NP carriage with antibiotic-non-susceptible pneumococci was 
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relatively constant throughout the first year of life. PCV13 serotypes were more commonly 























Nasopharyngeal (NP) colonization by antimicrobial-resistant Streptococcus pneumoniae 
(pneumococcus) is a global public health concern.1 The pneumococcus is an important 
bacterial cause of childhood pneumonia, meningitis, and sepsis.2,3 NP colonization with 
pneumococci is a prerequisite for development of pneumococcal disease.4 The nasopharynx 
of children serves as a natural reservoir for pneumococci and the source for person to 
person transmission.5 Vaccination with pneumococcal conjugate vaccine (PCV) is effective in 
reducing both vaccine type pneumococcal carriage and invasive disease.6 Despite this, 
carriage prevalence has remained unchanged due to an increase in carriage of non-vaccine 
serotypes which also contribute to resistance.7 
A rise in antibiotic resistance among pneumococci has reduced the effectiveness of empiric 
antibiotics used to treat pneumococcal infections.8 Beta-lactam antibiotics are commonly 
used for the treatment of infections caused by pneumococci.9 Widespread beta-lactam 
prescription and routine immunization exert selective pressures on the pneumococcal 
population structure which contribute to the emergence of beta-lactam resistant-
pneumococci.5,9 This has in turn resulted in the increased use of other classes of antibiotics 
such as macrolides and fluoroquinolones. Transmission of pneumococci that are resistant to 
these classes of antibiotics is also increasing in certain parts of the world, more so following 
the widespread PCV use.10 
Detection of antibiotic resistance is important for successful therapy in the individual child, as 
well as for tracking antibiotic resistance patterns, which inform empiric treatment guidelines, 
and antimicrobial stewardship.11 Most studies on the NP carriage of antibiotic-resistant 
pneumococci are cross sectional, and there are few longitudinal studies describing 
pneumococcal resistance patterns, including duration of carriage of susceptible and resistant 
pneumococci especially in low and middle income country settings where there is the 
greatest burden of disease.12,13 This study aimed to investigate antimicrobial resistance 
patterns in pneumococci colonizing the nasopharynx of PCV13 vaccinated South African 
infants, from birth through the first year of life. 
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3.2 Material and methods 
3.2.1 Study population and sampling 
NP swabs were collected fortnightly from 137 infants enrolled between May 29th  2012 and 
May 31st 2014 as part of intensive cohort of the Drakenstein Child Health Study (DCHS), a 
longitudinal, prospective birth-cohort study in the Drakenstein sub-district, Cape Town, South 
Africa.14 The study population is a stable, semi-urban community with a low socioeconomic 
status. This area also has a high incidence of childhood pneumonia (incidence 0.29 
episodes/child year).15 Pregnant women (>18 years) were enrolled in public sector health 
clinics during the second trimester, and followed until childbirth. Thereafter, infants were 
enrolled at birth and followed through their first year of life.14 All births occurred at Paarl 
Hospital, a single public hospital serving this area. All 137 infants received a 2+1-dosing 
schedule of PCV13 at 6 weeks, 14 weeks and 9 months of age, according to the South 
African Expanded Program on Immunization (EPI-SA, 2015). For this study we included the 
first 137 infants enrolled in the cohort who had the most complete fortnightly NP sampling 
(defined as at least 23-26 fortnightly collected NP swabs). 
3.2.2 Bacterial isolates 
The NP sample collection, transportation, culture and storage have been described 
previously.16 Briefly, the NP swabs were placed into 1ml skim milk-tryptone-glucose-glycerol 
(STGG) immediately after collection and transported at 4°C to the laboratory within two hours 
of collection (if not cultured immediately, the samples were stored at -80°C for later batch 
culture). Pneumococcal isolates were previously identified by colony morphology, alpha-
hemolysis, optochin disc susceptibility (Oxoid, Basingstoke, UK) and confirmed by using the 
lytA polymerase chain reaction (PCR).17 The isolates were stored in 1 ml skim milk-tryptone-
glucose-glycerol (STGG) medium at -80°C for further analyses. The isolates were 
resuscitated by inoculating 20 µl of thawed STGG onto 2% sheep blood agar (Green Point 
Media Laboratory, National Health Laboratory Service, Cape Town, South Africa) and 
incubated for 24-48 hours at 37°C, in 5% CO2. 
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3.2.3 Antibiotic susceptibility testing (AST) 
Susceptibility testing of the isolates to oxacillin (1 µg), erythromycin (5 µg) and cotrimoxazole 
(1.25-23.75 µg) (bioMérieux, Marcy I’Etoile, South Africa) was performed using the disc 
diffusion method and interpreted according to CLSI 2017 guidelines (Clinical Laboratory 
Standards Institute, 2017). The isolates that were non-susceptible to oxacillin on disc 
diffusion underwent minimum inhibitory concentrations (MIC) testing. This was determined by 
using benzyl penicillin/penicillin G E-test (bioMérieux, Marcy I’Etoile, South Africa) according 
to the manufacturer’s instructions, and interpreted using CLSI 2017 guidelines (Clinical 
Laboratory Standards Institute, 2017). A subset of 243 randomly selected isolates were 
screened for resistance to ciprofloxacin (5 µg) and levofloxacin (5 µg) (bioMérieux, Marcy 
I’Etoile, South Africa).  This subset was tested to check if there was any fluoroquinolone non-
susceptible isolate; these antibiotics are not recommended as the primary antibiotics to be 
tested (Clinical Laboratory Standards Institute, 2017). S. pneumoniae ATCC 49619 and 
Staphylococcus aureus ATCC 25923 were used as quality control strains. Oral penicillin 
breakpoints were used to interpret penicillin results (susceptible: ≤ 0.06 µg/ml, intermediate: 
0.12 – 1 µg/ml, resistant: ≥ 2 µg/ml). Intermediate (low-level resistance) and resistant (high-
level resistance) isolates were all considered as non-susceptible isolates. Multi-drug 
resistance was defined as non-susceptibility to the three classes of antibiotics (penicillin, 
erythromycin, and cotrimoxazole) tested and dual-resistance as non-susceptibility to two 
classes of antibiotics. To calculate the prevalence of non-susceptible isolates, longitudinal 
isolates from a single infant with the same antibiogram and serotype were classified as a 
single isolate (duplicate isolates). The acquisition of a non-susceptible pneumococcal isolate 
was defined as the detection of a non-susceptible isolate for the first time in an infant or the 
detection of a non-susceptible isolate that was initially susceptible. Loss of a non-susceptible 
isolate was similarly defined. The acquisition of a non-susceptible pneumococcal isolate was 
presumed to start at the mid-point between the last sampling time-point before which the 
non-susceptible isolate was detected and the time-point at which the non-susceptible isolate 
was first identified, whilst a loss of a non-susceptible isolate was considered as the mid-point 
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between the time at which the non-susceptible isolate was last identified and the next time-
point. The carriage duration was determined by the difference between the loss date and 
acquisition date.16  
3.2.4 Ethical considerations 
This study was carried out in accordance with the recommendations of the Human Research 
Ethics Committee of the Faculty of Health Sciences, University of Cape Town. The protocol 
was approved by the Human Research Ethics Committee of the Faculty of Health Sciences, 
University of Cape Town (HREC refs: 401/2009 and 740/2013) and the Western Cape 
Provincial Child Health Research Committee. All subjects gave written informed consent in 
accordance with the Declaration of Helsinki. 
3.2.5 Statistical analysis 
Statistical analyses were performed using STATA software (Stata Corporation, College 
Station, TX). Chi-square and Fisher’s exact tests were used where applicable to compare the 
differences in the prevalence of carriage of non-susceptible pneumococci. Unpaired t-test 
(mean-comparison test) was used to compare the mean carriage durations. A two-tailed p-
value of <0.05 was considered statistically significant. 
3.3 Results 
3.3.1 Participant demographics 
Of 137 infants included in this study, 56% (77/137) were female and 6% (8/137) were 
preterm. The majority of infants were born via vaginal delivery (80%, 109/137), followed by 
emergency caesarean section (13%, 18/137), and elective caesarean section (7%, 10/137). 
Only 7% (10/137) of the infants were admitted to a ward after birth whereas 93% (127/137) 
roomed with their mother. Overall, 25% (34/137) of infants were born to HIV-infected 
mothers, with only one infant being HIV-infected (Table 3.1). PCV13 immunization coverage 
was 100% at 6 weeks, 14 weeks, and 9 months scheduled visit, respectively. Despite this, 
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immunization was delayed by at least 2 weeks in 6% (8/137) and 18% (24/137) of the infants 




Table 3.1: Characteristics of infants included in this study 
Characteristics % (Total), N = 137 
Gender:  
          Female 56 (77) 
Mode of delivery:  
          Vaginal 80 (109) 
          Emergency caesarean 13 (18) 
          Elective caesarean 7 (10) 
Preterm (< 37 weeks) 6 (8) 
Low birth weight (< 2500g) 13 (18) 
HIV exposure# 24 (33) 
Admission after birth:  
          Ward 7 (10) 
          Roomed with the mother 93 (127) 
Breastfed before discharge 89 (119) 
PCV13 immunization  
          6 weeks* 100 (137) 
          14 weeks 100 (137) 
          9 months** 100 (137) 
#One of the 33 HIV-exposed infants was HIV-infected. 
*Immunization delayed by at least 2 weeks in 8 infants. 
**Immunization delayed by at least 2 weeks in 24 infants. 
 
3.3.2 Antibiotic susceptibility patterns among non-duplicate isolates 
Fifty percent (760/1520) of isolates were non-duplicate pneumococcal isolates. Of these, 
49% (376/760, [95% confidence interval, CI 46-53%]) were susceptible to all three antibiotics 
tested (penicillin, erythromycin, and cotrimoxazole). In total, 19% (147/760, [95% CI 17-
22%]), 18% (136/760, [95% CI 15-21%]) and 45% (344/760, [95% CI 42-49%]) were non-
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susceptible to penicillin, erythromycin and cotrimoxazole, respectively (Table S3.1). Three 
percent (21/760, [95% CI 2-4%]), 14% (108/760, [95% CI 12-17%]), and 36% (274/760, [95% 
CI 33-40%]) of the non-susceptible isolates were fully resistant to penicillin, erythromycin, 
and cotrimoxazole, respectively. None of the 243 randomly selected isolates were non-
susceptible to ciprofloxacin or levofloxacin. 
3.3.3 Serotype distribution and antibiotic susceptibility patterns  
Non-PCV13 serotypes (n = 528) were more commonly isolated than PCV13 serotypes (n = 
133). However, PCV13 serotypes were more likely to be non-susceptible than non-PCV13 
serotypes to penicillin, erythromycin and cotrimoxazole (Figure 3.1, Table 3.2 and Table 
S3.1). The rates of dual resistance and multi-drug resistance (MDR) were low, ranging from 
3% to 9% for penicillin-erythromycin dual resistance and MDR, respectively (Table 3.2 and 
Table S3.1). A significantly higher proportion of PCV13 serotypes had dual penicillin-
cotrimoxazole resistance (12%; 16/133 vs. 5%, 28/528, P = 0.003) and dual erythromycin-
cotrimoxazole resistance (11%, 14/133 vs. 4%, 20/528, P = 0.001), compared to non-PCV13 
serotypes.  The overall prevalence of MDR was 9% (68/760, [95% CI 7-11%]), which was 
higher (but not significant) for PCV13 than non-PCV13 serotypes (10%, 13/133 vs. 7%, 
39/528, P = 0.244) (Table 3.2 and Table S3.1). The most frequent MDR PCV13 serotypes 
were 19F (6%, 4/68) and 19A (4%, 3/68), while non-PCV13 serotypes included 15B/15C 
(15%, 10/68), 16F (6%, 4/68), 13 (6%, 4/68), and 15A (6%, 4/68) (Table S3.1). The 
predominant penicillin-non-susceptible pneumococci were non-typeable isolates (19%, 
28/147), serotypes 15B/15C (14%, 20/147), 19A (9%, 13/147), 15A (7%, 10/147), 19F (5%, 
8/147), and 21 (5%, 8/147). Of note, penicillin-non-susceptible isolates were frequently also 











Table 3.2: Proportion of antibiotic-non-susceptible pneumococcal isolates, obtained from 
137 infants, by vaccine type 
Antibiotic(s) % non-susceptible isolates (95% confidence interval) P-valuea 
PCV13 serotypes  
(n = 133) 
Non-PCV13 serotypes  
(n = 528) 
Penicillin 26 (19-34) 16 (13-19) 0.007 
Erythromycin 23 (16-30) 15 (12-18) 0.027 
Cotrimoxazole 62 (53-70) 41 (37-46) <0.001 
Penicillin + erythromycin 2 (0-5) 3 (2-4) 0.532 
Penicillin + cotrimoxazole 12 (8-19) 5 (4-8) 0.003 
Erythromycin + cotrimoxazole 11 (6-17) 4 (2-6) 0.001 
MDR 10 (6-16) 7 (5-10) 0.244 
a Difference between PCV13 vs. non-PCV13 serotypes. PCV13 serotypes- Serotypes included in 
the 13-pneumococcal conjugate vaccine, Non-PCV13 serotypes- Serotypes not included in the 13-
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Figure 3.1: Serotype frequency and susceptibility profiles of 760 non-duplicate pneumococcal 
isolates obtained from 137 infants, by serotype. Susceptibility to (A) penicillin, (B) erythromycin, 
and (C) cotrimoxazole. Others include serotypes 20, 38, 11F, 18A, 19B, 19C, 22A/F, 23B, 25A/38, 
33B/35C, 33F, 47F, and 6C/D. PCV13 serotypes- Serotypes included in the 13-pneumococcal 
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conjugate vaccine, Non-PCV13 serotypes- Serotypes not included in the 13-pneumococcal 
conjugate vaccine, NT- Non-typeable. 
 
3.3.4 Antibiotic non-susceptibility trends over time 
None of the infants were colonized by pneumococci at birth, thereafter, colonization with any 
pneumococci was detected from 2 weeks of which 20% (95% CI 0-72%) were non-
susceptible to penicillin (Figure 3.2). NP carriage of penicillin-non-susceptible pneumococci 
was observed as early as 2 weeks of age, however, erythromycin- and cotrimoxazole-non-
susceptibility were only observed at week 4; 13% (95% CI 4-29%) and 41% (95% CI 24-
59%), respectively. Although there was a slight decline in penicillin-non-susceptibility 
between weeks 22 to 32 (≤ 10%), the levels of non-susceptibility to penicillin, erythromycin, 
and cotrimoxazole remained relatively constant through the first year of life (X2 test for trend: 
p = 0.184, range 0 – 25%; p = 0.171, range 0 – 27%; and p = 0.572, range 0 – 55%, 
respectively) (Figure 3.2). Non-susceptibility to more than one antibiotic class among the 
pneumococcal serotypes is shown in Supplementary Figure S3.1. Although prevalence of 
non-susceptibility to more than one antibiotic class was generally low, the frequency of dual 
resistance to penicillin-cotrimoxazole was higher during the first six months of life (range 0 – 
13%) and then declined over the next six months of life (range 0 – 6%) (X2 test for trend, p < 
0.001). There were no other clear trends for changes in the prevalence of dual or multi-drug 






































































PCV13 Non-PCV13 Pen-non-susceptibility (Overall)






































































PCV13 Non-PCV13 Ery-non-susceptibility (Overall)






































































PCV13 Non-PCV13 Sxt-non-susceptibility (Overall)






Figure 3.2: Point-prevalence of antibiotic-non-susceptible pneumococci (n = 1520) obtained from 137 
infants throughout the first year of life, (A) penicillin-non-susceptibility, (B) erythromycin-non-susceptibility, 
and (C) cotrimoxazole-non-susceptibility. Pen- Penicillin, Ery- Erythromycin, Sxt- Cotrimoxazole, No- 
Number, PCV13 serotypes- Serotypes included in the 13-pneumococcal conjugate vaccine, Non-PCV13 
serotypes- Serotypes not included in the 13-pneumococcal conjugate vaccine. 
 
3.3.5 Relationship between antibiotic non-susceptibility and duration of carriage 
The mean carriage duration for all pneumococcal serotypes ranged from 13 to 65 days; the 
mean carriage duration for individual serotypes has been previously described.16 Overall, 
penicillin or erythromycin-non-susceptible pneumococci were carried for a shorter duration 
than susceptible pneumococci, and the difference in the mean carriage duration was 
significant: penicillin-non-susceptible (18 days, 95% CI 17-20) vs. penicillin-susceptible (21 
days, 95% CI 20-22), p = 0.013 and erythromycin-non-susceptible (18 days, 95% CI 16-21) 
vs. erythromycin-susceptible (21 days, 95% CI 20-22), p = 0.035. Cotrimoxazole-non-
susceptible and -susceptible pneumococci were carried for similar durations (21 days, 95% 
CI 19-22, and 20 days, 95% CI 19-22, respectively, p = 0.766) (Table 3.3).  
When stratified according to serotype, penicillin or erythromycin-non-susceptible non-PCV13 
serotypes were carried for a shorter duration than susceptible non-PCV13 serotypes: 
penicillin (mean days, 18 vs. 22 respectively, p = 0.019) and erythromycin (mean days, 17 
vs. 22 respectively, p = 0.007), (Table 3.3). These findings were reversed for PCV13 
serotypes;  non-susceptible PCV13 serotypes were carried for a longer duration than 
susceptible PCV13 serotypes but this was not statistically significant for penicillin or 
erythromycin: penicillin (mean days, 20 vs. 19 respectively, p = 0.621), erythromycin (mean 
days, 23 vs. 20 respectively, p = 0.122), and cotrimoxazole (mean days, 22 vs. 17 
respectively, p = 0.027). These difference were largely due to serotypes 19F and 9V (PCV13 
serotypes) which were carried for a longer duration if non-susceptible: serotype 19F, for 





Table 3.3: Carriage duration of antibiotic-non-susceptible pneumococcal isolates, obtained from 
137 infants, by vaccine type 
Antibiotic 
susceptibility 







 Penicillin      
      Non-susceptible 18 (17-20) 16 (13-23) 20 (18-23) 18 (15-19)  0.313 
      Susceptible 21 (20-22) 17 (15-20) 19 (17-21) 22 (21-23)  0.033 
 Erythromycin      
      Non-susceptible 18 (16-21) 15 (14-16) 23 (17-29) 17 (14-20)  0.037 
      Susceptible 21 (20-22) 17 (15-18) 20 (18-22) 22 (21-24)  0.086 
Cotrimoxazole       
      Non-susceptible 21 (19-22) 16 (14-17) 22 (19-25) 21 (19-23)  0.649 
      Susceptible 20 (19-22) 17 (15-18) 17 (14-20) 21 (20-23)  0.030 
a Difference between PCV13 vs. non-PCV13 serotypes. PCV13 serotypes- Serotypes included in 
the 13-pneumococcal conjugate vaccine, Non-PCV13 serotypes- Serotypes not included in the 13-
pneumococcal conjugate vaccine. 
 
3.3.6 Changes in antibiotic susceptibility pattern within the same infant 
Changes in antibiotic susceptibility profiles within the same pneumococcal serotype carried 
by an infant were observed in 45% (61/137) of infants (Figure 3.3). Of the 104 shifts in 
susceptibility profiles observed in these infants, 76% (79/104) were for penicillin, including 
changes from susceptible to non-susceptible (n = 41) and non-susceptible to susceptible 









Figure 3.3: Longitudinal carriage of pneumococci showing shifts in antibiotic-non-susceptibility profiles which occurred in 61 out of 137 infants. PCV13 






This study reports the antimicrobial-non-susceptibility patterns of pneumococci colonizing the 
nasopharynx of PCV13 vaccinated South African infants. Despite high vaccine coverage, 
PCV13 serotypes were identified in 54% of children and these were more commonly non-
susceptible to penicillin, erythromycin, and cotrimoxazole than non- PCV13 serotypes. The 
point-prevalence of antibiotic-non-susceptible pneumococci to penicillin, erythromycin, and 
cotrimoxazole was relatively constant from week 4 through the first year of life. Overall, 
penicillin or erythromycin-non-susceptible pneumococci, irrespective of serotype, were 
carried for a shorter duration than penicillin or erythromycin-susceptible pneumococci.  
There are limited data on the NP carriage of antibiotic-non-susceptible pneumococci among 
vaccinated children during the first year of life.19–21 The prevalence of penicillin-non-
susceptible pneumococci was 19% in this study. The rate of non-susceptibility was higher 
compared to that reported among infants in India (3.4%),19 Fiji (11.4%),21 and The Gambia 
(13.3%).20 The majority of the isolates in the present study displayed intermediate resistance 
to penicillin, in line with other studies.22 Serotypes 15B/15C, 19A, and 15A showed the 
highest non-susceptibility to penicillin and this finding has been documented in other 
studies.23,24 The prevalence of erythromycin-non-susceptible pneumococci in the current 
study was 18%, which was higher than that reported in The Gambia (0%),20 and in Fiji 
(11.6%),21 but lower than 37% reported in India.19 Factors associated with high antibiotic-
non-susceptibility in the current study could not be determined due to the limited sample 
size.  
Compared to penicillin and erythromycin, the prevalence of cotrimoxazole-non-susceptible 
isolates in this study was high (45%). Russell et al. reported a relatively low cotrimoxazole 
non-susceptibility level of 20.3% among Fijian children within the same age group.21 
However, high cotrimoxazole non-susceptibility rates have been reported among Gambian 
(60%),20 and Indian (81%),19 children less than one year of life. In South Africa, 
cotrimoxazole is given as prophylaxis to individuals who are HIV-infected or exposed. Infants 
are administered cotrimoxazole prophylaxis from 4 or 6 weeks of life until the child is 
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confirmed HIV-uninfected.25 Twenty-four percent (33/137) of the infants in this study were 
born to mothers who were HIV-infected, which may have contributed to the high levels of 
cotrimoxazole non-susceptibility observed. There was no difference in the proportion of 
carriage of cotrimoxazole-non-susceptible pneumococci between infants born to HIV-
infected vs. HIV-uninfected mothers. However, this analysis was not included due to the 
small sample size, and inability to test significance. The acquisition of cotrimoxazole-non-
susceptible pneumococci from the mother or other sources cannot be disregarded since 
cotrimoxazole is widely used in low and middle income countries including South Africa.26 
None of the selected pneumococcal isolates were non-susceptible to ciprofloxacin or 
levofloxacin. Fluoroquinolones, particularly, levofloxacin, gatifloxacin, and moxifloxacin are 
increasingly used for the treatment of community-acquired pneumonia,27 especially in high 
income countries where tuberculosis is less prevalent.28 These antibiotics are uncommonly 
used in the public health sector, including the clinics and hospital that our population 
accessed. However, non-susceptibility to levofloxacin has emerged in several countries and 
this poses a threat to its ability to treat resistant pneumococcal infections.29–33 
This study showed that PCV13 serotypes were still circulating and had higher proportions of 
antibiotic-non-susceptibility than non-PCV13 serotypes, and this has been observed 
elsewhere.34,35 In the current study, this might be attributable to the time elapsed between 
PCV13 implementation in 2011 (in South Africa) and the commencement of the study in 
2012. However, a study in The Gambia reported the persistence carriage of vaccine 
serotypes even five years after the introduction of PCV13.36 Interestingly, antibiotic-non-
susceptibility among non-typeable pneumococci was also frequent. Although non-typeable 
pneumococci have limited potential for disease, they may act as a reservoir for the transfer 
of antibiotic resistance elements to other bacteria. Monitoring of resistance levels and 
colonization rates of non-typeable pneumococci is therefore important.37 In addition, the 
current study did not investigate whether the capsule gene among non-typeable 
pneumococci was down regulated or switched, therefore, further investigation is warranted. 
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Few studies have reported on the carriage duration of antibiotic-non-susceptible 
pneumococci, with most focused on individuals with respiratory tract infection.12,38,39 The 
carriage duration of penicillin-non-susceptible pneumococci (mean 18 days) in this study was 
lower than that reported among Swedish infants with respiratory tract infection (mean 49 
days).12 In this study, duration of carriage was related to both serotype (PCV13 vs. non 
PCV13) and antibiotic non-susceptibility. Firstly, we observed that penicillin or erythromycin-
non-susceptible pneumococci were carried for a shorter duration than penicillin or 
erythromycin-susceptible pneumococci. This may also have been likely due to the serotypes 
that were carried or may suggest that a fitness cost could be associated with expression of 
antibiotic resistance.40,41 Our finding was however dependent on serotype since penicillin, 
erythromycin or cotrimoxazole-non-susceptible PCV13 serotypes were carried for a longer 
duration than susceptible PCV13 serotypes, while the inverse was true for non-PCV13 
serotypes. Penicillin-non-susceptible serotype 19F and erythromycin-non-susceptible 
serotypes 19F and 9V were carried for a longer duration than the other PCV13 serotypes. 
One possible explanation for our findings is that, in pneumococci, the relative fitness cost of 
particular non-susceptible genotypes may depend on the genetic background of the strains 
in which the resistance-conferring mutations or genes are found.40 Further work, using whole 
genome sequencing to identify the resistance-conferring genes and strain genetic 
background is needed.    
Dual resistance and MDR were generally low, however, significantly higher rates of dual 
resistance were observed among PCV13 serotypes compared to non-PCV13 serotypes for 
penicillin-cotrimoxazole (12% vs. 5%, p = 0.003) and erythromycin-cotrimoxazole (11% vs. 
4%, p = 0.001). Penicillin-non-susceptible pneumococci have been shown to be frequently 
non-susceptible to other classes of antibiotics.42 In the current study, penicillin-non-
susceptible pneumococcal isolates were frequently non-susceptible to erythromycin and 
cotrimoxazole, as described elsewhere.9,43,44  
This study documented shifts in the antibiotic susceptibility profiles over time within the same 
pneumococcal serotype carried by an infant. Seventy-six percent (79/104) of the shifts 
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observed were for penicillin susceptibility profiles, however, since genetic resistance 
determinants were not investigated, we are unable to confirm whether switches in resistance 
occurred within the same strain, or identify the genetic basis of resistance acquisition or loss, 
and this should be addressed in future studies. 
There were several limitations to this study. Firstly, pneumococcal isolates were only 
screened against five commonly used antibiotics. Secondly, the infants enrolled were from 
the same geographic district, therefore the results may not be generalizable. This cohort 
included only vaccinated infants, and no case control of unvaccinated children could be 
made.  The methods used in this study were unable to detect co-colonization with multiple 
serotypes or confirm or characterise genetic resistance determinants. A further limitation is 
the inability to determine risk factors associated with antibiotic non-susceptibility and carriage 
duration of non-susceptible pneumococci due to the small sample size. This study does 
however provide baseline data on the prevalence, trends, and carriage duration of antibiotic-
non-susceptible pneumococci among infants enrolled in a PCV13 immunized birth cohort in 
a low and middle income country setting with a high incidence of lower respiratory tract 
infection in infants.15 
In conclusion, this study showed that the NP carriage of antibiotic-non-susceptible 
pneumococci was relatively constant through the first year of life. Despite a high vaccine 
coverage, PCV13 serotypes were identified and were more commonly non-susceptible to 
penicillin, erythromycin, and cotrimoxazole. Overall, penicillin or erythromycin-non-
susceptible pneumococci were carried for a shorter duration than susceptible pneumococci, 
however, non-susceptible PCV13 serotypes were carried for a longer duration than non-
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Shotgun metagenomic sequencing of nasopharyngeal (NP) samples, from children enrolled 
in a PCV13-vaccinated South African birth cohort was used to explore strain-level 
pneumococcal colonization patterns and associated antimicrobial resistance determinants. 
NP swabs were collected at two week intervals from birth through the first year of life from 
137 infants. Pneumococcal isolates were serotyped and tested for phenotypic antimicrobial 
resistance. 196 NP samples from a subset of 23 infants were then selected based on 
changes in serotype or antimicrobial resistance. DNA extraction and shotgun metagenomic 
sequencing were performed directly from enriched NP samples. Reads were assembled and 
aligned against reference pneumococcal genomes. In-silico pneumococcal capsular, 
multilocus sequence typing, and resistome analyses were performed. Of the 196 samples 
sequenced, 174 had corresponding positive cultures for pneumococci and, of those 152 
were assigned an in-silico serotype. Metagenomic sequencing detected a single 
pneumococcal serotype in 85% (129/152), and co-colonization in 15% (23/152) of the 
samples, respectively. The concordance between Quellung/sequetyping and shotgun in-
silico typing was 86% (127 out of 148 NP samples that were assigned a serotype by both 
methods). Twenty-two pneumococcal serotypes were identified, with 15B/15C (n = 49) and 
16F (n = 21) being the most common non-PCV13 serotypes, while 23F (n = 9) and 19A (n = 
8) were the most common PCV13 serotypes. 26 different sequence types (STs), including 4 
novel STs were identified in-silico. Mutations in the folA and folP genes, associated with 
cotrimoxazole resistance, were detected in 89% (87/98) of cotrimoxazole-non-susceptible 
pneumococci, as well as in the pbp1a and pbp2x genes, in penicillin non-susceptible 
ST705215B/15C isolates. Metagenomic sequencing of nucleic acid from NP samples is a 
valuable culture-independent technique for a detailed evaluation of the pneumococcal 






Streptococcus pneumoniae (the pneumococcus) is a frequent bacterial cause of infections 
such as bacterial pneumonia, otitis media, meningitis, sinusitis, and bacteraemia in young 
children, and is a major cause of morbidity and mortality.1–4 Globally, pneumococcal 
pneumonia was responsible for an estimated 393,000 deaths in children less than five years 
of age in 2015.5 Asymptomatic pneumococcal nasopharyngeal (NP) carriage is common 
among infants, a reservoir for transmission and precedes the development of disease.6 
Pneumococci are classified into more than 100 serotypes, based on the antigenic specificity 
of the polysaccharide capsule.7,8 Children are often sequentially colonized by multiple 
different serotypes,9,10 and may be co-colonized by different pneumococcal serotypes at the 
same time.11 
Immunization with the pneumococcal conjugate vaccine (PCV) has substantially reduced NP 
carriage and invasive pneumococcal disease caused by, serotypes represented in the 
vaccine.12,13 In addition, the introduction of PCV has also resulted in a reduction in 
antimicrobial resistance amongst circulating pneumococci due to the inclusion of serotypes 
associated with high antibiotic resistance in the conjugate vaccine.14 However, non-vaccine-
serotypes have emerged among both carriage and disease-causing isolates, and are 
increasingly associated with antimicrobial resistance.15,16 Increasing pneumococcal 
resistance to different classes of antibiotics, including beta-lactams, macrolides, 
tetracyclines, and cotrimoxazole, has compromised the effectiveness of antibiotics to treat 
pneumococcal infections.17 
Pneumococci are most commonly identified from samples using bacterial culture followed by 
phenotypic and genotypic characterization of the isolates.18,19 The Quellung reaction, which 
is based on antigen-antibody reaction, is currently the gold standard for pneumococcal 
serotyping, but requires viable isolates in pure culture. To detect colonization with multiple 
serotypes, typing of many individual (often identical) pneumococcal colonies from each NP 
sample is often required.20 Sequential multiplex PCR assays are increasingly used for 
serotyping, and can be done directly on the NP sample, however, this is relatively laborious, 
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costly, and limited to serotypes targeted by the PCR.21 None of these methods are able to 
provide a more detailed, strain-level characterization, important for pneumococci, as 
capsular switching often results in different serotypes within the same lineage.22 
Metagenomic approaches, where the collective genomes of all organisms recovered directly 
from a sample are sequenced, is a high-throughput approach to investigate the members of 
a microbial community in an ecological niche, and represents an alternative to culture-
dependent methods for microbial characterization. In this study, we explored the use of 
shotgun metagenomic sequencing to characterize the pneumococcal component of the NP, 
including identification of co-colonization with multiple serotypes and antimicrobial 
resistance, among PCV-vaccinated children participating in a South African birth cohort. 
4.2 Materials and methods 
4.2.1 Study population and sampling 
Children were enrolled in a longitudinal birth-cohort study, the Drakenstein Child Health 
Study,23 in the Western Cape Province of South Africa. NP swabs were collected every 
second week from birth through the first year of life from 137 infants.10 Infants received 2+1 
doses of 13-valent pneumococcal conjugate vaccine (PCV13) at 6 weeks, 14 weeks, and 9 
months according to the national immunization program in South Africa. Details of the study 
population and sampling have been previously described.23 The study was approved by the 
University of Cape Town, Faculty of Health Sciences Human Research Ethics Committee 
(Reference numbers 401/2009 and 235/2016). Written informed consent was obtained from 
mothers. 
4.2.2 Identification and antimicrobial characterization of pneumococci 
The collected NP swabs were immediately placed into 1 ml skim milk-tryptone-glucose-
glycerol (STGG) medium, transported on ice, and stored at -80°C until further batch 
processing. A 10 µl aliquot of the NP-STGG was inoculated onto a blood agar plate (Oxoid 
Columbia base with 5% sheep blood) containing gentamicin (5 µg/ml) and incubated 
overnight at 37°C, in 5% CO2. Presumptive pneumococcal isolates were identified as 
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previously described;24 only a single pneumococcal isolate was selected for characterization 
from each sample. The isolates were serotyped using sequetyping and confirmed by 
Quellung as previously described.25,26 
Susceptibility to oxacillin, erythromycin, and cotrimoxazole were assessed using the disc 
diffusion method, and interpreted using Clinical and Laboratory Standards Institute (CLSI) 
guidelines.27 Penicillin minimum inhibitory concentrations (MICs) were determined using the 
E-test method (bioMérieux, Marcy I’Etoile, France), according to the manufacturer’s 
instructions. Resistant- and intermediate-resistant pneumococcal isolates were collectively 
regarded as non-susceptible. 
4.2.3 Broth enrichment of NP samples for pneumococci 
For this exploratory study, in order to explore the utility of metagenomic sequencing to detect 
colonization with multiple serotypes and identify antimicrobial resistance determinants, a 
total of 196 NP-STGG samples were purposively selected from a subset of 23 of the 137 
infants described above, based on changes in serotype and antibiogram over time identified 
using phenotypic methods (The selection of isolates based on changes in serotypes or 
antimicrobial resistance applies to 61 infants in total as described in Chapter 3. However, it 
was not possible to select all 61 infants and all their samples for shotgun sequencing). The 
NP-STGG samples were enriched as previously described, with minor modifications.28 
Briefly, 200 µl of an NP-STGG sample was transferred to 6 ml Todd-Hewitt Broth (without 
antibiotics), containing 0.5% yeast extract and 17% foetal bovine serum. The liquid culture 
was incubated at 37°C with 5% CO2, without shaking for 6 hours. The culture was then 
centrifuged at 12,000 x g for 10 minutes at 4°C. Total nucleic acid extraction was performed 
on the collected pellet using the QIAsymphony SP automated platform (Qiagen, Hilden, 
Germany) with the QIAsymphony Virus/Bacteria Mini Kit (Cat. No. 931036) following the 
manufacturer’s instructions. Nucleic acid concentrations and purity were determined using 
the NanoDrop® ND-100 (Thermo Fishers Scientific, Waltham, USA). 
4.2.4 Metagenomic DNA sequencing, assembly and in-silico typing 
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Total nucleic acid was subjected to shotgun sequencing on the MiSeq platform using the 
MiSeq Reagent Kit v3 (600-cycle) (Illumina, San Diego, USA) at the J. Craig Venter Institute, 
Rockville, USA. Metagenomic DNA sequencing protocols and the pipeline used to assemble 
the reads and evaluate the assembly have been previously described.28  Reads were 
assembled using metaSPAdes,29 and aligned to the created serotype nucleotide database 
using BLASTn, with an identity over 98% considered a match.28 In addition, assembly-based 
in-silico multi-locus sequence typing (MLST) was performed using LOCUST as previously 
described.30,31 
Serotypes identified by Quellung and sequetyping on isolates,26 were compared to in-silico 
serotypes identified from metagenomic sequences obtained directly from NP samples. 
Culture-based and metagenomic-assigned serotypes were considered concordant if the 
serotype detected by Quellung/sequetyping was detected by shotgun sequencing (either as 
a single serotype or amongst co-colonizing serotypes detected). 
4.2.5 Phylogenetic tree construction 
A phylogenetic tree of pneumococcal genomes was constructed to assess strain 
relatedness. Assembly-based (metaSPAdes assembler) variant calling,29 was performed 
using The Northern Arizona Single Nucleotide Polymorphism Pipeline (NASP).32 All 
completed pneumococcal genomes available on the NCBI database were included in the 
NASP run and the S. pneumoniae R6 genome (Accession number AE007317) was used as 
a reference genome. The aligned base calls for each of the core variant positions identified 
by NASP were used for the construction of the maximum likelihood tree.33 
4.2.6 Analysis of genetic determinants of antimicrobial resistance  
Pneumococcal contigs (contigs that mapped to reference pneumococcal genome R6) were 
compared to the Antibiotic Resistance Gene-Annotation (ARG-ANNOT) database by BLAST 
alignment.34 Results were filtered using ≥ 90% sequence identity over 80% of the sequence 
length of the reference antibiotic resistance gene as cut-offs. The pbp1a, pbp2x, pbp2b, folA 
(encoding dihydropteroate synthase (DHPS)), and folP (encoding dihydrofolate reductase 
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(DHFR)) gene mutations associated with resistance to beta-lactams, trimethoprim, and 
sulfonamides respectively, were investigated by manual local alignment, as the ARG-
ANNOT database does not automatically detect these mutations. The ARG-ANNOT 
database only included the pbp1a (JN645776) and pbp1b (AF101781) genes of wild-type 
pneumococcal strains. Therefore, local alignments of the pbp1a (JN645776.1), pbp2x 
(JN645706.1), pbp2b (DQ056780.1), folA_R6 (Gene ID 4442919), and folP_R6 (Gene ID 
4443057) were performed using BLASTn (80% identity and 60% gene length coverage).  
For each individual, and for each of the genes, sequences from the longitudinal samples 
were aligned with Multiple Alignment using Fast Fourier Transform (MAFFT).35 Aligned 
sequences were viewed and translated to amino acids in AliViewer (version 1.18.1) for 
active site mutation analysis. The transpeptidase domains of the pbp1a, 2x, and 2b, from the 
wild type S. pneumoniae R6 strain were used as references. Phylogenetic trees were 
constructed with Molecular Evolutionary Genetic Analysis software (MEGA version 7.0.26) 
using a neighbour-joining method and bootstrapping 1000 replicates. pbp1a (JN645776.1), 
pbp2x (JN645706.1), and pbp2b (DQ056780.1) were used as reference gene sequences in 
the construction of the phylogenetic trees. 
4.3 Results 
4.3.1 Participant characteristics 
Shotgun sequencing was used to study the pneumococcal population structure in the 
selected subset of 196 NP samples from 23 infants. The number of NP samples selected for 
sequencing ranged from 4 – 21 samples per infant (average of 8.5 samples); selected 
samples and age at sampling (average 14.9 weeks) for each of the infants is shown in 
Figure 4.1. Thirteen of the infants were males (57%). The mean birth weight was 3.0 kg 
(range, 2.4 – 3.8 kg) with only one preterm infant. Eight infants were HIV exposed (born to 
HIV-infected mothers) but were HIV-uninfected (more detailed clinical characteristics of 23 




Figure 4.1: This figure indicates the number of samples selected for metagenomic sequencing and serotype assignments for the 196 nasopharyngeal (NP) 
samples selected from 23 infants (shown in rows 1 to 23). None of the infants were colonized until 4 weeks of age. Small dots indicate that samples were 
collected. Large circles (colours represent serotype group) represent the collected NP samples selected for shotgun metagenomic sequencing. Split circles 
represent samples with co-colonization with multiple serotypes. In-silico serotypes are displayed for samples selected for shotgun metagenomic sequencing. (-) 
Indicates that no sample was collected at that time point. (nt) Non-typeable. 
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4.3.2 Metagenomic sequencing results 
The average number of reads per sample was 13 million (ranging from 80 thousand – 93 
million reads per sample) despite low input DNA concentrations (data not shown). The 
average number of microbial reads that mapped to the R6 pneumococcal reference genome, 
per sample, was 4.5 million (range, 141 reads – 32 million reads per sample) with an 
average coverage of 308.53X (range, 0.01X – 2239.71X).  
4.3.3 In-silico serotypes and sequence types 
Of the 196 samples sequenced, 174 had a corresponding positive pneumococcal culture. 
Shotgun sequencing detected pneumococcal reads in all 174 samples, however, 15 samples 
had no reads covering the desired regions (cps, housekeeping genes, and core variant 
positions identified by the NASP) of the pneumococcal genomes and were excluded from 
further analyses. In-silico serotypes from shotgun sequencing were assigned in 96% 
(152/159) of the remaining samples and serotypes were assigned in 93% (148/159) of 
samples by both Quellung/sequetyping and shotgun sequencing. The concordance between 
Quellung/sequetyping and shotgun in-silico typing was 86% (127/148) (Table S4.1). Co-
colonization with two (n = 22) or three (n = 1) different serotypes was detected in 15% 
(23/152) of the samples from 10 infants using shotgun sequencing. Since 
Quellung/sequetyping typing was only done on a single colony per sample, co-colonization 
was not detected using this method.  
Non-PCV13 serotypes were more commonly detected than PCV13 serotypes (Figure 4.1). 
Twenty-two different pneumococcal serotypes were identified in-silico, with 15B/15C (n = 
49), 16F (n = 21), 10A (n = 21), 13 (n = 14), and 21 (n = 12) being the most common non-
PCV13 serotypes, and 23F (n = 9) and 19A (n = 8) being the most common PCV13 
serotypes. Serotypes and STs identified are shown in Table S4.2. MLST was assigned in 
89% (142/159) of the samples representing 26 different MLST profiles (Figure 4.2). The 
common STs detected include ST868715B/C (n = 28/142), ST564713 (n = 13/142), ST206810A 
71 
 
(n = 12/142), and ST705215B/C (n = 10/142). Four novel STs (ST1379515B/15C, ST1379734, 
ST1379823B, and ST1379921) were also identified (Figure 4.2 and Table S4.2). 
Figure 2
 
Figure 4.2: A maximum likelihood whole genome phylogenetic tree of pneumococcal isolates 
recovered from 23 infants. Bootstrap values are shown on each branch and the scale bar represents 
the number of single-nucleotide polymorphisms (SNPs). Circles with the same colour represent 
longitudinal samples from the same infant. Numbers in brackets indicate the age in weeks at each 
time-point. The sequence type (ST) detected in each sample is shown as a number, followed by the 
associated serotype. Serotypes indicated in red were among co-colonizing strains and had genomes 
with lower coverage than the other co-detected strain. Five out of 15 samples that had low reads 
mapping to pneumococcal genomes are indicated in blue text. NT- Non-typeable. Completed 
pneumococcal genomes available on the NCBI database were included and the R6 genome was 
used as a reference. The samples clustered according to ST but not serotype. Persistent colonization 
with the same genotype was common. 
72 
 
4.3.4 Antimicrobial resistance determinants 
Phenotypic antibiotic susceptibility profiles were determined for the 159 pneumococcal 
isolates obtained from samples included for this analysis.36 Overall, 18% (29/159), 17% 
(28/159), and 61% (98/159) of the isolates were non-susceptible to penicillin, erythromycin, 
and cotrimoxazole respectively. 
Using in-silico analyses, a total of 48 acquired antimicrobial resistance (AMR) genes were 
identified from pneumococcal contigs in 20 samples collected from 10 infants (Figure 4.3). 
The AMR genes detected included macrolide-lincosamide-streptogramin B resistance 
(MLSB) (msrD, mefA and ermB), and tetracycline resistance (tetM) genes (Figure 4.3). The 
average sequence length coverage across the reference genes was 99% (range, 81-100%) 
while the average sequence depth was 160X (range, 1-411X).  
Phenotypic non-susceptibility to erythromycin was detected in 18% (28/159) of isolates 
(Figure 4.3). Among the 28 samples from which these isolates were obtained, genes 
predicted to confer macrolide non-susceptibility were detected in 39% (11/28) of samples 
[msrD and mefA (n = 9), mefA (n = 1), and ermB (n = 1)] from three infants. In addition, 
macrolide resistance genes were detected in a further six samples (from five infants) that 
were culture negative for pneumococci (Figure 4.3); two of these samples had co-
colonization with multiple serotypes. 
Pneumococcal pbp genes were analysed for mutations associated with beta-lactam 
resistance. No indels were identified in any of the extracted pbp gene sequences, but 
multiple amino acid changes were identified at various positions within the transpeptidase 
domains. Pneumococcal isolates with penicillin MICs between 0.064 and 8.0 µg/ml 
commonly carried mutations within the transpeptidase domains of the pbp1a and pbp2b 
genes, but not in pbp2x (Figure S4.1), compared to the wild-type pneumococcal strain R6. 
Pbp point mutations known to contribute to beta-lactam resistance are shown in Table S4.3. 
The S351A and P432T point mutations (known to confer beta-lactam resistance) which are 
73 
 
within or close to the conserved motifs of the pbp1a gene were identified in penicillin-non-
susceptible ST705215B/15C (n = 9), ST36135B (n = 1), and ST206810A (n = 1) isolates from four 
infants (Figure 4.3 and Table S4.3). Amino acid substitution H394L (known to confer beta-
lactam resistance), in the pbp2x gene, was only identified among PCV13 serotypes 23F (n = 
9), 19A (n = 4), and 6A (n = 2), from four infants, irrespective of penicillin susceptibility 
(Table S4.4). These serotypes (23F, 19A, and 6A) had identical amino acid sequences of 
the transpeptidase domain of the pbp2x gene despite having different STs (Figure S4.3). 
Pneumococcal strains encountered in this study had a higher divergence in the 
transpeptidase domain sequences of the pbp1a and pbp2x genes than in the pbp2b gene 
(Figure S4.2, S4.3, and S4.4). 
Ninety-eight out of 159 (62%) isolates were phenotypically non-susceptible to cotrimoxazole 
(Figure 4.3). The folA (I100L) and folP (6-bp insertion in the region encoding amino acid 58 
to 67) gene mutations, known to confer resistance to cotrimoxazole,37,38 were detected in 
89% (87/98) of the samples from which the non-susceptible isolates were obtained (Figure 
4.3 and Table S4.4). Combinations of resistance mutations including I100L plus R59P60 (n = 
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Figure 4.3: Shotgun seque ce-derived molecular seque ce type and resistome (from direct sequencing of NP swabs), and phenotypic antimicrobial susceptibility 
results (from pneumococcal isolates) in 159 out of 19  NP samples obtained from 23 infants (assigned  to 23, top row). (a) In-silico sequence types (STs) and 
associated serotypes detected in longitudinal NP samples from each infant. (b) pbp gene mutations and associated penicillin phenotypic susceptibility profiles; light 
blue colour indicates wild-type pbp genes; the dark blue colour indicates detected mutations within or close to the conserved motifs for the pbp genes. (c) Macrolide-
resistance genes and associated erythromycin phenotypic susceptibility profiles; the dark blue colour indicates detected resistance genes. (d) folA and folP gene 
mutations and associated cotrimoxazole phenotypic susceptibility profiles; light blue colour indicates wild-type folA and folP genes; dark blue colour indicates 
detected mutations, in folA and folP, that reduce the affinity of trimethoprim or sulfamethoxazole. (e) Detected tetracycline resistance gene; dark blue colour indicates 




This study explored the use of shotgun metagenomic sequencing as an alternative approach 
to culture-based testing to study pneumococcal NP colonization and associated antimicrobial 
resistance determinants, in a South African birth cohort. We were able to derive 
pneumococcal serotypes and sequence types and to identify co-colonisation and 
antimicrobial resistance determinants directly from shotgun sequence data. Since NP 
samples from apparently healthy individuals generally have low numbers of bacterial cells, 
we used short-term broth enrichment, which has previously been shown to successfully 
enrich streptococci.28  
There was complete concordance between detection of pneumococcal sequences and 
positive culture for pneumococci. However, of the 174 samples sequenced, which were also 
culture positive, 15 samples produced poor sequence read mapping to the reference 
pneumococcal genomes, despite good overall read counts. These 15 samples were 
excluded from further analyses as they are likely other Streptococcus species. There was 
good correlation (86%) between conventional typing methods and shotgun sequencing in 
assigning pneumococcal serotypes. Discordant serotype results were predominantly from 
samples where only one serotype was identified by shotgun sequencing, and were therefore 
not due to detectable co-colonization. Both Quellung and sequetyping are not infallible in 
assigning pneumococcal serotypes.21 Shotgun metagenomic sequencing produced robust 
serotyping results, based on sequence coverage and depth, but this technique is, at present, 
relatively expensive, time consuming, and computationally intensive for routine typing.39 
Whole-genome sequencing of cultured pneumococcal isolates produces reliable serotyping 
results and can generate additional genetic information, but it is mostly performed on single 
isolates, and may thus fail to detect co-colonization, or exclude samples with non-viable 
bacteria.40 On the other hand, microarray techniques which may or may not require a 
culture-enrichment step has been shown to have the potential to detect multiple serotypes 
within a sample, however, this technique can only detect serotypes included on the array.41 
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Eleven percent (17/159) of the samples could not be assigned a multilocus sequence type 
due to a lack of resolution at all the loci necessary for typing. This was frequently observed 
in samples where co-colonization with multiple serotypes was detected, or in samples with 
low estimated sequencing coverage.28 In samples where sequence types were assigned, we 
observed a strong association between certain pneumococcal serotypes and multilocus 
sequence types. However, serotypes 15B/15C (ST7052, ST8687, and ST13795) and 16F 
(ST4088 and ST3450/ST10673) were associated with multiple STs. Serotypes 15B/15C and 
16F were the predominant serotypes detected in our cohort, and highly prevalent serotypes 
tend to be more diverse.42 No other ST in our collection was associated with more than one 
serotype, in line with previous observations.43 
Shotgun sequencing detected co-colonization with multiple serotypes in 15% of the samples; 
these would have been difficult or laborious to detect when using Quellung method, since 
multiple colonies would have to be tested individually, or pooled colonies tested with multiple 
reagents.40 This rate of co-colonization was lower than that reported in Malawi among 
children aged 0 – 13 years (40%, 46/116),44 but comparable to that reported among children 
less than 2 years of age in Tehran (17%, 225/1302).45 In the current study, serotype 19A 
isolates (from two infants) were only detected using shotgun sequencing (and not culture), in 
samples with multiple serotypes. Detection of circulating serotype 19A is important in 
epidemiological studies, since 19A is included in the PCV13 administered to infants. Culture-
dependent techniques are biased to detect the most abundant serotype in a sample and are 
likely to miss co-colonization with less abundant serotypes.46 Carriage of multiple 
pneumococcal serotypes is also important since it provides an opportunity for horizontal 
gene transfer, which is one of the most common mechanisms driving pneumococcal 
evolution.47 
To date, 11 STs identified in this study, including ST205923F, ST206219A, and ST1082319F, 
matched other STs which have only been described among isolates from South Africa 
(https://pubmlst.org), and may therefore be unique to South Africa. These strains are 
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associated with serotypes included in the PCV13, which is currently administered in the 
South African routine immunization schedule, and which all infants in this study received. 
Five STs (ST206810A, ST345016F, ST335831, ST19919B, and ST39338) identified here are 
reported for the first time in an African country (https://pubmlst.org). Additionally, four novel 
STs were identified, namely: ST1379515B/15C, ST1379734, ST1379823B, and ST1379921. 
The AMR genes identified by pneumococcal resistome analysis were msrD, mefA, ermB, 
and tetM. Macrolide-resistance genes (msrD, mefA, or ermB), predicted to confer resistance, 
were detected in 11/28 NP samples with erythromycin-non-susceptible pneumococci. 
Acquired AMR genes were not detected in the remaining samples, and the resistance 
observed could be due to other mechanisms of macrolide resistance not investigated here.48 
The frequency of msrD or mefA was higher than that of ermB, and this is in contrast to what 
has been reported in other studies, including South Africa.49,50 TetM gene was detected in 8 
samples but this could not be associated with phenotypic resistance as isolates in this study 
were not tested for susceptibility to tetracycline, since it is not routinely used to treat 
pneumococcal infections. 
A proportion of 62% (98/159) of cotrimoxazole non-susceptibility was observed in 
pneumococcal isolates contained in samples included for shotgun sequencing. 
Cotrimoxazole, which is a combination of trimethoprim and sulfamethoxazole, inhibits folic 
acid biosynthesis, and non-susceptibility to this drug is conferred by the acquisition of 
mutations in folA and folP.37 The majority of cotrimoxazole-non-susceptible isolates (81%) in 
the current study possessed the I100L amino acid substitution in DHFR, and this mutation 
has been shown to be sufficient to confer high-level cotrimoxazole resistance.37,38 The most 
common insertions detected in DHPS led to the duplication of R58P59 and S62Y63 in 56% and 
27% of cotrimoxazole-non-susceptible isolates, respectively. These insertions have been 
shown to confer low-level cotrimoxazole resistance.37,38 Most instances (71/86) of high-level 
cotrimoxazole resistance observed were due to both folA I100L substitution and folP 
insertion, and this has been previously described.51 Lack of associations in other isolates 
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might be due to other mechanisms of resistance or loss of expression of the detected 
mutations.51  
Pbp genes code for the penicillin-binding proteins (PBPs) which are essential for cell 
envelope bio-synthesis and are the target for beta-lactam antibiotics.52 Gene mutations 
occurring within or close to the pbp-conserved motifs within the transpeptidase domain are 
known to confer resistance to beta-lactams.53 Amino acid alterations in pbp1a, pbp2b, and 
pbp2x have been shown to be the most reliable markers for beta-lactam-resistance in 
pneumococci.54 A higher level of variation in the transpeptidase domain sequences of pbp1a 
and pbp2x, than in pbp2b was observed (Figure S4.2, S4.3, and S4.4). The pbp1a and 
pbp2x genes flank the capsule (cps) locus, which is prone to frequent recombination 
events,55 and recombination events involving the cps locus and one or both pbp1a and/or 
pbp2x genes have been observed.56 This could account for the higher level of variation 
observed in the pbp1a and pbp2x genes among the strains here.   
In this study, penicillin non-susceptibility was observed mainly in isolates carrying the P432T 
(in pbp1a) and T338P (in pbp2x) mutations. The P432T and T338P mutations were detected 
in all 9 penicillin-non-susceptible, ST705215B/15C isolates, from two infants. The P432T 
mutation, which is close to the 428SRN430 conserved motif,54 and the T338P mutation, 
occurring within the active 337STMK340 motif,57 decrease beta-lactam-binding affinity of 
PBP1a and PBP2x, respectively. The contribution of other mutations to penicillin non-
susceptibility among our strains was unclear (Table S4.3). 
This study was limited to a small sample size and the use of metagenomic sequencing in 
samples obtained from a larger population is warranted. NP samples were enriched using 
broth without antibiotics and this may have favoured other bacteria more than pneumococci 
thus leading to inability to assemble the pneumococcal genomes in samples with low 
sequence reads. The description of antibiotic use and detection of antibiotic resistance 
genes has bee described in Chapter 5 and no intensive analyses were done due to small 
sample size, and incomplete data on antibiotic usage in this cohort. 
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Using shotgun sequencing, we were able to derive pneumococcal serotype and sequence 
type, and to detect co-colonisation, and antimicrobial resistance determinants directly from 
enriched NP samples. Direct shotgun sequencing from enriched NP samples is therefore a 
promising technique for detailed evaluation of the pneumococcal component of the NP 
microbiome, and its use should be explored similarly for other bacteria in this niche. 
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Table S4.1: Comparison between shotgun sequencing and conventional 
methods for pneumococcal serotyping 
No. of infants 
Detected pneumococcal serotypes (no. of samples) 
Comment 
Shotgun sequencing Conventional methods 
3 13 (13) 13 (11) Concordant 
  
23A (1) ˣ 
  
16F (1) ˣ 
2 21 (5) 21 (4) Concordant 
  
16F (1) ˣ 
1 31 (1) 31 (1) Concordant 
1 34 (4) 34 (2) Concordant 
  
21 (1) ˣ 
  
16F (1) ˣ 
3 10A (12) 10A (11) Concordant 
  
22F (1) ˣ 
1 15A (1) 15A (1) Concordant 
7 15B/15C (45) 15B/15C (42) Concordant 
  
10A (1) ˣ 
  
35B/C (1) ˣ 
  
nt (1) ˣ 
3 16F (14) 16F (11) Concordant 
  
9V (2) ˣ 
  
6C (1) ˣ 
1 18B (1) 18B (1) Concordant 
1 19B (2) 19B (2) Concordant 
1 19F (2) 19F (2) Concordant 
1 23B (5) 23B (3) Concordant 
  
11A (1) ˣ 
  
nt (1) ˣ 
1 23F (9) 23F (1) Concordant 
  
9V (6) ˣ 
  10A (1) ˣ 
  
13 (1) ˣ 
2 35B (2) 35B (2) Concordant 
1 6A (1) 6A (1) Concordant 
1 6B (2) 6B (2) Concordant 
1 6C (6) 6C (6) Concordant 
1 7C (1) 7C (1) Concordant 
1 9N (3) 9N (3) Concordant 
1 19A, 10A (7) 10A (6) Concordant 
  19A (1) Concordant 
1 6A, 21, 34 (1) 6A (1) Concordant 
1 10A, 35B (1) 19C (1) ˣ 
1 10A, 16F (1) 16F (1) Concordant 
2 21, 16F (6) 21 (3) Concordant 
  16F (3) Concordant 
1 6B, 15B/15C (2) Nt (2) ˣ 
1 31, 35B (1) 35B (1) Concordant 
1 13, 15A (1) 13 (1) Concordant 
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1 15B/15C, 23A (1) 23A (1) Concordant 
1 23B, 38 (1) 23B (1) Concordant 
1 19A, 15B/15C (1) 19A (1) Concordant 
7 nt (7) * ˣ 
12 Negative1 (22) Negative2 (22) Concordant 
* 15B/15C (4), 10A (1), 19F (1), and 15A (1). 1 No pneumococcal reads detected, 2 Culture-
negative for pneumococcus. (ˣ) Discordant results. Conventional and metagenomic-
assigned serotypes were considered concordant if the serotype detected by conventional 
methods was among the co-colonizing serotypes. 
 
 
Table S4.2: Distribution of in-silico serotypes, associated STs, and MLST profiles. 
Serotype 
Sequence type  
(no. of 
samples) 
No. of  
infants 
MLST allelic profile  Other serotypes associated with 
the ST described1 aroE gdh gki recP spi xpt ddl  
15B/15C ST8687 (28) 3 1 32 97 5 10 88 18  6A 
 ST7052 (10) 2 7 43 47 16 6 14 17  none 
 ST13795* (8) 2 2 13 14 1 17 4 14  none 
13 ST5647 (13) 3 15 5 54 1 197 1 168  none 
10A ST2068 (12) 3 2 40 4 19 10 1 27  none 
23F ST2059 (8) 1 15 29 4 21 30 27 1  6A, 19A, 19F 
19A ST2062 (6) 2 1 5 53 32 14 20 199  none 
16F ST3450 (6) 1 1 5 14 5 15 1 1  none 
 ST4088 (5) 1 50 8 1 16 6 88 14  none 
 ST10673 (3) 1 1 5 14 4 15 1 1  none 
6C ST7345 (6) 1 1 10 9 43 15 1 17  none 
21 ST13799* (6) 1 50 10 2 16 1 834 1  none 
 ST10854 (4) 1 8 10 2 138 1 26 1  none 
23B ST13798* (5) 1 7 608 8 6 25 6 8  none 
34 ST13797* (4) 1 12 5 54 38 27 14 18  none 
9N ST3983 (3) 1 8 5 7 12 15 16 6  9V 
19B ST199 (2) 1 8 13 14 4 17 4 14  19A, 15B/15C, 3 
6A ST1447 (2) 1 6 13 8 6 25 6 8  23F, 35B 
31 ST3358 (2) 1 1 2 29 1 43 14 8  none 
19F ST10823 (2) 1 10 25 9 10 6 4 168  none 
6B ST471 (2) 1 7 25 4 4 15 1 28  6A 
35B ST361 (1) 1 7 13 8 6 6 6 8  1, 23F, 6A, 6B, 19A, 23B 
38 ST393 (1) 1 10 43 41 18 13 49 6  25A, NT 
18B ST4893 (1) 1 2 5 2 16 1 26 1  18C 
7C ST8838 (1) 1 7 8 146 15 25 20 5  none 
15A ST10605 (1) 1 2 18 6 10 17 12 19  none 
1 Other serotypes associated with sequence types described in this study as listed in the PubMLST global database. * 











Amino acid substitution at position:a 
PBP1a  PBP2x  PBP2b 
351 371 432  338 394 546  451 614 624 629 
Ref R 6  S S T P  T H L  T L A A 
 NT NT I A . T  X X X  X X X X 
 ST7052 15B/15C I A . T  P . .  A A . N 
2 ST7052 15B/15C I A . T  P . .  A A . N 
 ST7052 15B/15C I A . T  P . .  A A . N 
 ST7052 15B/15C I A . T  P . .  A A . N 
 ST7052 15B/15C I A . T  P . .  A A . N 
 ST7052 15B/15C I A . T  P . .  A A . N 
7 ST7052 15B/15C I A . T  P . .  A A . N 
 ST7052 15B/15C I A . T  P . .  A A . N 
 ST7052 15B/15C I A . T  P . .  A A . N 
 nt 35B S A A T  A . V  A T G . 
 nt 15B/15C S X X X  P . .  X X X X 
 ST7052 15B/15C S X X X  P . .  X X X X 
4 ST361 35B I A . T  . . .  A S . E 
1 ST1447 6A S . . .  . L .  A S . E 
 ST1447 6A S X X X  . L .  A S . E 
3 ST10823 19F S . . .  . . .  A . . . 
 ST10823 19F S . . .  . . .  A . . . 
 ST2059 23F S . . .  . L .  A . . . 
 ST2059 23F S . . .  . L .  A . . . 
 ST2059 23F S . . .  . L .  A . . . 
17 ST2059 23F I . . .  . L .  A . . . 
 ST2059 23F S . . .  . L .  A . . . 
 ST2059 23F R . . .  . L .  A . . . 
 ST2059 23F S . . .  . L .  A . . . 
 nt 23F S . . .  . L .  A . . . 
 ST2059 23F S . . .  . L .  A . . . 
10 ST2062 19A S . . .  . L .  X X X X 
20 ST2068 10A I A S T  A . V  A . . . 
 ST2062 19A S . . .  . L .  A . . . 
 ST2062 19A S . . .  . L .  A . . . 
 ST2062 19A S . . .  . L .  A . . . 
22 ST13798 23B S . . .  . . .  A S . E 
 ST13798 23B I . . .  . . .  A S . E 
 ST13798 23B S . . .  . . .  A S . E 
 ST13798 23B S . . .  . . .  A S . E 
 ST13798 23B S . . .  . . .  A S . E 
16 nt 13 S . . .  A . V  A T G . 
1 Assigned infant number. Only mutations at positions within or close to the conserved motifs in the transpeptidase 
domain in PBP1a (370STMK373, 428SRN430), PBP2x (337STMK340, 395SSN397, 547KSG549), and PBP2b (448SSN450, 
619KTG621) are shown. a Identity with the amino acid from S. pneumoniae strain R6 is indicated by the dot. (X)- The 
gene was not detected. Pen- penicillin, Ery- erythromycin, Sxt- cotrimoxazole, NT- non-typable, S- Susceptible, I- 





Table S4.4: Amino acid variation of DHFR (folA) and DHPS (folP) associated 
with cotrimoxazole non-susceptibility 
Cotrimoxazole  
phenotype  





Amino acid mutations 
folA 
substitution folP insertion 
Resistant (n = 86)    
 45 (8) I100L R58P59 
 24 (4) I100L S62Y63 
 2 (1) I100L S61S62 
 3 (3) I100L - 
 1 (1) I100L wt 
 2 (2) wt R58P59 
 1 (1) wt S62Y63 
 1 (1) - R58P59 
 7 (6) wt wt 
Intermediate (n = 12)    
 3 (2) I100L R58P59 
 1 (1) I100L S62Y63 
 4 (2) wt R58P59 
 4 (3) wt wt 
Susceptible (n = 5)    
 3* (2) I100L S62Y63 
 2  (2) I100L R58P59 



















































Amino acid substitution in PBP1a (wild type-position-mutation)
Amino acid substitution in PBP2x (wild type-position-mutation)






Figure S4.1: Codons with mutations within the transpeptidase domains of penicillin-binding proteins (PBPs). (a) PBP1a; (b) PBP2x; (c) 
PBP2b. Only amino acids that differ from the R6 wild-type strain (GenBank accession no. AE007317.1) are shown. Mutations at positions 
within or close to each of the conserved penicillin-binding motifs (370STMK373 and 428SRN430 in PBP1a, 337STMK340, 395SSN397, and 547KSG549 in 





Figure S4.2: Phylogenetic tree, based on the transpeptidase domain of the pbp1a gene constructed, 
by MEGA using the neighbour-joining method. Bootstrap values (percentage) are based on 1,000 
replications. The scale bar represents the genetic divergence as calculated by the MEGA software. 
Same colour represents the longitudinal samples from the same infant. The number in brackets 
indicate the age in weeks at each time-point. The ST detected in each sample is shown as a number, 






Figure S4.3: Phylogenetic tree, based on the transpeptidase domain of the pbp2x gene, constructed 
by MEGA using the neighbour-joining method. Bootstrap values (percentage) are based on 1,000 
replications. The scale bar represents the genetic divergence as calculated by the MEGA software. 
Same colour represents the longitudinal samples from the same infant. The number in brackets 
indicate the age in weeks at each time-point. The ST detected in each sample is shown as a number, 







Figure S4.4: Phylogenetic tree, based on the transpeptidase domain of the pbp2b gene, constructed 
by MEGA using the neighbour-joining method. Bootstrap values (percentage) are based on 1,000 
replications. The scale bar represents the genetic divergence as calculated by the MEGA software. 
Same colour represents the longitudinal samples from the same infant. The number in brackets 
indicate the age in weeks at each time-point. The ST detected in each sample is shown as a number, 















Longitudinal changes in the nasopharyngeal 
antibiotic resistome in South African infants 















Nasopharyngeal (NP) colonization with antimicrobial-resistant bacteria is a global public 
health concern. Antimicrobial resistance (AMR) genes carried by the resident NP microbiota 
may serve as a reservoir for transfer of resistance elements to opportunistic pathogens. Little 
is known about the NP antibiotic resistome. This study longitudinally investigated the 
composition of the NP antibiotic resistome in Streptococcus-enriched samples in a South 
African birth cohort. NP swabs were obtained fortnightly from 137 infants from birth through 
the first year of life. Samples were cultured for pneumococci and isolates serotyped and 
antimicrobial susceptibility profiles determined. 196 longitudinal NP samples from a subset of 
23 infants were selected based on changes in serotype and antibiogram over time. NP 
samples underwent short-term enrichment for streptococci, and total nucleic acid was 
extracted for whole metagenome shotgun sequencing (WMGS). Reads were assembled and 
aligned to pneumococcal reference genomes for the extraction of pneumococcal and non-
pneumococcal bacterial reads. Contigs were aligned to the Antibiotic Resistance Gene-
ANNOTation database of acquired AMR genes. A total of 329 AMR genes were detected in 
64% (125/196) of the NP samples, including 36 non-redundant genes, ranging from 1 to 14 
genes per sample. The predominant AMR genes detected encoded resistance mechanisms 
to beta-lactam (52%, 172/329), macrolide-lincosamide-streptogramin (17%, 56/329), and 
tetracycline antibiotics (12%, 38/329). MsrD, ermB, and mefA genes were only detected from 
pneumococcal reads. The predominant genes detected from non-pneumococcal reads 
included blaOXA-60, blaOXA-22, and blaBRO-1. Different patterns of carriage of AMR genes were 
observed, with only one infant demonstrating stable carriage of mefA, msrD, and tetM over a 
long period. This study demonstrates that WMGS can provide a broad snapshot of the NP 
resistome and has the potential to provide a comprehensive assessment of all resistance 






Infection with antibiotic-resistant bacteria is a major public health concern due to the limited 
availability of new treatment options.1 Increasing antibiotic resistance has been noted in 
respiratory tract commensal bacteria which are capable of causing life-threatening 
infections.2,3 The upper respiratory tract, including the nasopharynx, is the reservoir for many 
respiratory pathogens and may also serve as a source for the horizontal transfer of 
antimicrobial resistance (AMR) genes from non-pathogenic to pathogenic bacteria.4 
Commensal and potentially pathogenic bacteria which commonly colonize the upper airways 
include Streptococcus pneumoniae (the pneumococcus), Staphylococcus aureus, 
Haemophilus influenzae, and several Gram-negative bacilli.5–7 The pneumococcus and H. 
influenzae are among the leading causes of bacterial respiratory tract infections in young 
children.8,9 Asymptomatic NP carriage of pneumococci is prevalent among infants and often 
precedes the development of disease.4,10 Drug-resistant pneumococci may cause difficult-to-
treat infections, associated with increased morbidity and mortality.4,10 In many cases, 
antibiotic resistance results from of horizontal gene transfer (HGT) of a mobile genetic 
element, or the uptake of free DNA from the surrounding environment,11,12 which is of 
particular importance as pneumococci are naturally competent, and can therefore readily 
take up exogenous DNA.13 
Culture-based methods only allow for the detection of certain AMR genes in viable, 
culturable bacteria, and are therefore unable to completely characterise the resistome in a 
particular niche.14 An alternative approach for the detection of all AMR genes is whole 
metagenome shotgun sequencing (WMGS) of the total DNA extracted directly from 
samples.15,16 The majority of  WMGS studies of the antibiotic resistome have focused on the 
human gut resistome,16–20 however to the best our knowledge there are no published studies 
of the NP antibiotic resistome. 
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We have previously reported changes in NP pneumococcal antibiotic resistance in infants 
studied longitudinally over the first year of life, using culture-based susceptibility testing.21 
Here, we further characterise a subset of these samples using WMGS, to demonstrate proof 
of concept for resistome analysis of upper respiratory tract samples. 
5.2 Material and Methods 
This study was nested within a longitudinal birth-cohort study, the Drakenstein Child Health 
Study (DCHS).22 The first 137 infants enrolled for the DCHS were selected and had NP 
swabs collected every second week from birth through the first year of life. The collected NP 
swabs were immediately placed into 1 ml skim milk-tryptone-glucose-glycerol (STGG) 
medium. The NP sample collection, storage, and culture for pneumococci have previously 
been described.23 The study was approved by the Faculty of Health Sciences Human 
Research Ethics Committee of the University of Cape Town (reference numbers: 235/2016 
and 401/2009) and informed consent obtained from all mothers. 
A total of 196 NP samples from a subset of 23 out of the 137 infants were purposively 
selected for shotgun metagenomic sequencing. The selection of NP samples was based on 
changes in pneumococcal serotype or in penicillin, and/or erythromycin susceptibility profiles 
over time.21 The NP-STGG samples were enriched as previously described, with minor 
modifications.24 Briefly, 200 µl of an NP-STGG sample was transferred to 6 ml Todd-Hewitt 
Broth (without antibiotics), containing 0.5% yeast extract and 17% fetal bovine serum. The 
broth was incubated at 37°C with 5% CO2, without shaking for 6 hours, then centrifuged at 
9000 rpm for 10 minutes at 4°C. Total nucleic acid extraction was performed on the collected 
pellet using the QIAsymphony SP automated platform (Qiagen, Hilden, Germany) with the 
QIAsymphony Virus/Bacteria Mini Kit (Cat. No. 931036) following the manufacturer’s 
instructions. Nucleic acid concentrations and purity were determined using the NanoDrop® 
ND-100 (Thermo Fishers Scientific, Waltham, USA). 
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Total nucleic acid was subjected to shotgun sequencing on the MiSeq platform using the 
MiSeq Reagent Kit v3 (600-cycle) (Illumina, San Diego, USA) at the J. Craig Venter Institute, 
Rockville, USA. Metagenomic DNA sequencing and assembly protocols have previously 
been described.24 Reads were assembled using metaSPAdes,25 and aligned to a database 
containing Streptococcus pneumoniae complete genomes in order to re-construct the 
pneumococcal genomes and extract all the pneumococcal contigs. Bacterial contigs not 
mapping to pneumococcal genomes were regarded as non-pneumococcal contigs and were 
separately extracted for further analysis.24  
Screening for AMR genes present in the selected NP samples was performed on the 
assembled contigs for both pneumococcal and non-pneumococcal contig datasets. Contigs 
were aligned to the Antibiotic Resistance Gene-ANNOTation (ARG-ANNOT) database of 
acquired AMR genes. To increase sensitivity for identifying novel genes or genotypes with 
low levels of similarity to the reference genes, less stringent criteria were used.26 A 
sequence with ≥ 90% identity,27 with an alignment coverage length of ≥ 25% to the reference 
gene sequence was designated as an AMR gene.26 The AMR genes were manually 
confirmed. 
Statistical analyses were performed using STATA (Stata Corporation, College Station, TX). 
Chi-square and Fisher’s exact tests were used to compare the differences in the proportion 
of samples with AMR genes. A p-value of <0.05 was considered statistically significant. 
5.3 Results 
5.3.1 Participants and metagenomic sample characteristics 
A total of 196 longitudinal NP samples were selected from 23 infants, with an average of 9 
selected NP samples per infant (range, 4 – 21 samples). The age at which the NP samples 
were collected spanned the first year of life with an average of 15 weeks. Four of the 23 
infants were born via caesarean section (Table 5.1). Eight infants were born to HIV infected 
mothers, but none of the infants were infected. Antibiotics were administered to 6 out of 7 
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infants who had severe or non-severe lower respiratory tract infection (LRTI) during the first 
year of life (ages, 0 – 52 weeks) (Table 5.1).  
 
Table 5.1: Clinical characteristics of the participants 
LRTI- Lower respiratory tract infection, PO- Oral antibiotic, IV-Intravenous antibiotic, Both- Ambulatory and acute care 
 
5.3.2 NP resistome characteristics 
The average depth of coverage of the detected AMR genes from all contigs was 26X (range 
1 – 862X). A total of 329 AMR genes were detected in 64% (125/196) of the selected NP 
samples. Among these, 57% (188/329) were detected at ≥ 90% identity and ≥ 25% gene 
Infant no. Mode of delivery HIV exposed 





Antibiotic for  
LRTI treatment (days) 
Admission for 
suspected LRTI 
1 Normal vaginal No 0 0 Erythromycin-PO (7 days)  
Amikacin-IV (5 days)  
Cefotaxime-IV (4 days)  
Gentamycin-IV (3 days)  
Meropenem-IV (3 days) 
- 
2 Normal vaginal No 8 8 Amoxicillin-PO (5 days) - 
3 Normal vaginal No - - - - 
4 Normal vaginal No - - - Ambulatory 
5 Emergency Caesarean section No - - - Ambulatory 
6 Normal vaginal Yes - - - Both 
7 Normal vaginal Yes - - - Unknown 
8 
Elective 
Caesarean section No - - - - 
9 Normal vaginal No - - - - 
10 Normal vaginal No 25 28 Amoxicillin-PO  Ambulatory 
11 Normal vaginal Yes - - - Ambulatory 
12 Normal vaginal Yes 8 - none Ambulatory 
13 Normal vaginal Yes - - - - 
14 Normal vaginal No - - - Ambulatory 
15 Normal vaginal No - - - - 
16 Emergency 
Caesarean section 
Yes 52 52 Amoxicillin-PO (5 days)  
Ampicillin-IV (1 day)  
Gentamycin-IV (1 day) 
Both 
17 Normal vaginal Yes 36 36 Amoxicillin-PO (8 days)  
Ampicillin-IV (1 day)  
Gentamycin-IV (1 day) 
Ambulatory 
18 Normal vaginal No - - - Ambulatory 
19 Normal vaginal No - - - Ambulatory 
20 Normal vaginal Yes - - - Hospitalized 
21 Normal vaginal No - - - Ambulatory 
22 Normal vaginal No 24 24 Amoxicillin-PO (5 days) Hospitalized 
23 Elective 
Caesarean section 
No - - - Ambulatory 
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coverage while only 30% (97/329) were detected at the more stringent cut-off of ≥ 90% 
identity and ≥ 80% gene coverage (Table 5.2). The number of resistance genes detected per 
sample ranged from 1 – 14 genes (Figure 5.1), and included 36 non-redundant genes 
(Figure 5.2). AMR genes were detected in at least one sample from each of the 23 selected 
infants (Figure 5.3). The most common resistance genes detected were those conferring 
resistance to beta-lactams (52%, 172/329), macrolide-lincosamide-streptogramin antibiotics 
(MLS) (17%, 56/329), and tetracyclines (12%, 38/329) (Table 5.2 and Figure 5.2). A high 
number of AMR genes conferring resistance to MLS (n = 38), tetracyclines (n = 25), 
aminoglycosides (n = 17), fluoroquinolones (n = 4), and trimethoprim (n = 3) were detected 
at a cut-off of 90% identity over 50% gene coverage (Table 5.2). Different patterns of 
carriage of AMR genes were observed, with only one infant having a stable carriage of 
mefA, msrD and tetM over a long period (Figure 5.3). 
 
Table 5.2: AMR genes conferring resistance to various classes of antibiotics from 
196 NP samples using different stringency criteria. 
Antibiotic 
class 
Number of genes 
Total number (%) ≥ 90% ID 
≥ 25% Cov 
≥ 90% ID 
≥ 50% Cov 
≥ 90% ID 
≥ 80% Cov 
Bla 125 29 18 172 (52.3) 
MLS 18 4 34 56 (17.0) 
Tet 13 2 23 38 (11.6) 
AGly 11 8 9 28 (8.5) 
Phe 8 0 5 13 (4.0) 
Sul 10 1 1 12 (3.6) 
Flq 2 0 4 6 (1.8) 
Tmt 0 0 3 3 (0.9) 
Rif 1 0 0 1 (0.3) 
Total  188 44 97   329 (100.0) 
AMR- Antimicrobial resistance, Bla- Beta-lactam, MLS- Macrolide-lincosamide-
streptogramin, Tet- Tetracycline, AGly- Aminoglycoside, Phe- Chloramphenicol, Sul- 






5.3.3 Pneumococcal resistome 
Shotgun sequencing detected pneumococcal reads in all 174 samples that were culture 
positive for S. pneumoniae. Seventy AMR genes (four non-redundant genes) were detected 
from pneumococcal contigs; the average depth of coverage was 103X (range 1 – 411X). 
MLS and tetracycline resistance genes were the only genes detected from pneumococcal 
contigs. The most commonly detected gene was tetM (n = 23), followed by msrD (n = 22), 
mefA (n = 21), and ermB (n = 4). msrD, ermB, and mefA genes were only identified from 
pneumococcal contigs. The combination of msrD, mefA and tetM genes was detected in 10 
samples from 3 infants and all were identified on the same contig in 9 out of 10 samples. 
5.3.4 Non-pneumococcal resistome 
A total of 259 AMR genes were detected from non-pneumococcal contigs with an average 
coverage depth of 10X (range, 1 – 862X). Nine types of AMR genes were detected from 
non-pneumococcal contigs (Figure 5.3), with beta-lactam resistance genes (66%, 172/259) 
being the most commonly detected genes (Table 5.2 and Figure 5.2). The most commonly 
detected beta-lactam resistance gene was blaOXA-60, followed by blaOXA-22, blaBRO-1, blaTEM, 
blaBRO-2, cfxA, and blaZ (Figure 5.2). The fluoroquinolone resistance gene norA was detected 
in six samples from four infants (Figure 5.3). 
5.3.5 Association between antibiotic use and the NP resistome 
No significant difference was observed between the presence of AMR genes in samples 
collected before and after the treatment of LRTI (Figure 5.3). A large proportion of AMR 











































Figure 5.1: Distribution of antimicrobial resistance (AMR) genes within 196 longitudinal NP samples 
selected from 23 infants. 
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Figure 5.2: Frequency of antimicrobial resistance (AMR) genes within 196 longitudinal NP samples 
selected from 23 infants. MLS-Macrolide-lincosamide-streptogramin. (*) AMR genes detected from 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Indicate samples collected before antibiotic administration
Indicate samples collected after antibiotic administration
 
Figure 5.3: Antibiotic resistance genes detected from 196 longitudinal NP samples selected from 23 infants (assigned 1 to 23). (A) Pneumococcal resistome. (B) Non-
pneumococcal resistome. Blue line indicates samples collected before antibiotic administration, for lower respiratory tract infection. Red line indicates samples collected after 





This proof-of-concept study investigated the composition of the NP antibiotic resistome in an 
intensively sampled South African birth cohort. 329 AMR genes were detected across 64% 
of the selected NP samples using targeted enrichment culture and shotgun metagenomic 
sequencing. The average depth of coverage for the resistance genes from pneumococcal 
contigs (103X) was higher than that from non-pneumococcal contigs (10X). This observation 
is likely due to the short streptococcal enrichment culture step using Todd Hewitt broth 
(without antibiotics).24 
We detected more resistance genes using a lower stringency criterion of ≥ 90% identity over 
25% coverage of the reference gene, which has been shown to be more reliable than the 
more stringent criteria, in detecting AMR genes.27 Yang et al., reported a high accuracy 
(99%) for detecting AMR genes using these less stringent parameters in metagenomic 
analysis.28  In the current study, at least 25% gene coverage was used,26 and this cut-off 
was higher than the suggested coverage of ≥ 25 amino acids.28 Only 30% of the AMR genes 
were detected using ≥ 90% identity over 80% coverage of the reference gene.26 The more 
stringent parameters detected mainly MLS, tetracycline, and aminoglycoside resistance 
genes which are frequently carried by Streptococcus species, presumably due to the higher 
depth of coverage as a result of the enrichment step.29,30 
We observed differences in the types and numbers of AMR genes identified from 
pneumococcal and non-pneumococcal contigs. Except for one non-pneumococcal sample in 
which tetM was detected (possibly from a different species of Streptococcus); tetM, msrD, 
ermB, and mefA genes were only detected from pneumococcal contigs (contigs mapping to 
reference pneumococcal genomes) (Figure 5.3). The msrD, ermB, and mefA genes are most 
frequently detected among pneumococcal isolates.31 Pneumococci which are resistant to 
MLS antibiotics are commonly also resistant to tetracycline due to the insertion of an MLS 
gene into the conjugative transposons of the Tn916 family, which typically carry the tetM 
gene.32,33 Although transposon analyses were not evaluated in the current study, msrD and 
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tetM genes were commonly identified on the same contig (9/10 samples) suggesting they 
could be carried on the same transposon.33 
The predominant AMR genes detected from non-pneumococcal contigs were beta-
lactamase genes, specifically blaOXA-60, blaOXA-22, blaBRO-1, and blaTEM. All blaTEM gene variants 
detected in the current study codes for narrow spectrum beta-lactamase enzymes, and 
these have previously been detected in the Enterobacteriaceae, H. influenzae, and Neisseria 
gonorrhoea.34 The blaBRO-1 gene was more commonly detected than blaBRO-2 (Figure 5.2), 
both are typically found among Moraxella catarrhalis isolates, with blaBRO-1 more prevalent 
than blaBRO-2 in M. catarrhalis.35 
The blaOXA-60 and blaOXA-22 genes, encoding the chromosomal and inducible class D beta-
lactamases have only been described in Ralstonia pickettii or R. mannitolilytica.36–40 
Ralstonia sp. are Gram-negative, non-fermentative bacilli, commonly isolated from the 
respiratory tract and their carriage among infants in this study warrants further 
investigation.41 OXA-22 is an oxacillinase with the ability to hydrolyse narrow-spectrum beta-
lactams.40 Unlike OXA-22, the hydrolysis spectrum of OXA-60, although narrow, includes 
carbapenems. Whilst R. pickettii infrequently causes infections, the potential for transfer of 
this gene to other NP bacteria should be studied.36,39 
The norA gene, which encodes a fluoroquinolone efflux transporter protein, has been 
described mainly in Staphylococcus aureus and can render resistance to both 
fluoroquinolones and other classes of antibiotics with dissimilar structures.42,43 
Beta-lactamase genes were the most commonly detected resistance genes in the current 
study. Amoxicillin, a beta-lactam antibiotic, was the most commonly prescribed antibiotic for 
both acute and ambulatory care in children in this study, which could explain the high 
number and types of beta-lactamase genes detected in this study.44 
There were several limitations to the current study. Firstly, the enrichment culture for 
pneumococci altered the composition of the NP microbiome and the prevalence of the 
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different AMR genes detected may therefore differ from that found in tested samples without 
enrichment. Secondly, the purposively selected sample set is unlikely to be broadly 
representative of infants in this study, since only samples with changes in resistance or 
serotype were selected for this investigation. Thirdly, the reference database used for the 
resistome analysis is not comprehensive, and excludes chromosomal mutations associated 
with resistance. Penicillin resistance associated with pbp gene mutations, such as pbp1a 
and pbp2x, and trimethoprim sulphamethoxazole resistance, associated with folA I100L 
substitutions and folP insertions, would not be detected using this database, and these 
analyses must be done manually. 
This study demonstrates that WMGS can provide a broad snapshot of the NP resistome. 
Recent work has highlighted that the nasopharynx is a conducive environment for the 
exchange of AMR genes between related Streptococcus species responsible for respiratory 
tract infections in children.45 WMGS has the potential to provide a comprehensive 
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We longitudinally investigated antimicrobial resistance amongst pneumococci colonizing the 
nasopharynx of PCV13-vaccinated South African infants. We also explored strain-level 
pneumococcal colonization patterns and associated antimicrobial resistance determinants, 
and the composition of the NP antibiotic resistome using shotgun metagenomic sequencing.  
Carriage of NP antibiotic-non-susceptible pneumococci was relatively constant throughout 
the first year of life. Despite a high vaccine coverage, PCV13 serotypes were identified, and 
were more commonly non-susceptible to penicillin, erythromycin, and cotrimoxazole. These 
observations might be attributable to the time elapsed in South Africa between PCV13 
implementation in 2011 and the commencement of the study in 2012. Therefore, an 
extended follow-up period of more than a year may be necessary in order to observe 
significant changes in the carriage of antibiotic-non-susceptible pneumococci.  
Risk factors associated with the high antibiotic-non-susceptibility observed in this study could 
not be determined due to the small sample size and purposive sample selection strategy, 
therefore, future studies with a larger sample size, and unbiased selection strategy would 
allow for a detailed risk factor analysis. 
Antibiotic resistance in bacteria may be caused by different mechanisms which may not be 
detected using conventional methods. To identify the presence of additional resistance 
elements, more discriminatory genetic methods are needed to characterize the composition 
of the NP resistome. Our resistome analyses using shotgun metagenomic sequence data 
allowed for the differentiation of AMR genes identified from pneumococcal and non-
pneumococcal sequences.  
A limitation of our resistome analyses was that the results were based on shotgun 
metagenomic data and not on individual isolates. It was therefore difficult to link resistance 
genes identified in the clinical sample to individual isolates present, and future work will 
address this by employing WGS on individual isolates.  
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Children may be sequentially or concurrently colonized by different pneumococcal strains, 
yet current methods for the detection of co-colonization are limited. We explored the use of 
shotgun metagenomic sequencing to characterize the complete pneumococcal component 
of the NP microbiota in children. We were able to derive pneumococcal serotype, sequence 
type, co-colonisation, and antimicrobial resistance determinants directly from shotgun 
sequence data. We identified four novel sequence types and varying colonization patterns, 
per infant, over time. Direct shotgun sequencing from enriched NP samples is therefore a 
valuable technique for the detailed evaluation of the pneumococcal component of the NP 
microbiota. Our findings highlight the power of this technique to obtain a comprehensive 
assessment of the pneumococcal component of the NP microbiota, including colonization 
with multiple and novel genotypes. 
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